Author: "Isabelle Ollivier" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Isabelle Ollivier"' showing total 90 results

Start Over Author "Isabelle Ollivier"

90 results on '"Isabelle Ollivier"'

1. International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendations

Author: Jean-François David Cadranel, Isabelle Ollivier-Hourmand, Jacques Cadranel, Thierry Thevenot, Honoré Zougmore, Eric Nguyen-Khac, Christophe Bureau, Manon Allaire, Jean-Baptiste Nousbaum, Véronique Loustaud-Ratti, Xavier Causse, Philippe Sogni, Bertrand Hanslik, Marc Bourliere, Jean-Marie Peron, Nathalie Ganne-Carrie, Thong Dao, Dominique Thabut, Bernard. Maitre, Nabil Debzi, Ryad Smadhi, Roger Sombie, Raimi Kpossou, Olivier Nouel, Julien Bissonnette, Isaac Ruiz, Mourad Medmoun, Sergio Negrin Dastis, Pierre Deltenre, Florent Artru, Chantal Raherison, Laure Elkrief, and Tristan Lemagoarou
Subjects: Hepatic hydrothorax, Therapeutic pleural puncture, Albumin infusion, Spontaneous bacterial empyema, Talcage pleurodesis, Indwelling pleural catheter, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract: Abstract Background The Hepatic hydrothorax is a pleural effusion related to portal hypertension; its diagnosis and therapeutic management may be difficult. The aims of this article are which follows: To gather the practices of hepatogastroenterologists or pulmonologists practitioners regarding the diagnosis and management of the hepatic hydrothorax. Methods Practitioners from 13 French- speaking countries were invited to answer an online questionnaire on the hepatic hydrothorax diagnosis and its management. Results Five hundred twenty-eight practitioners (80% from France) responded to this survey. 75% were hepatogastroenterologists, 20% pulmonologists and the remaining 5% belonged to other specialities. The Hepatic hydrothorax can be located on the left lung for 64% of the responders (66% hepatogastroenterologists vs 57% pulmonologists; p = 0.25); The Hepatic hydrothorax can exist in the absence of clinical ascites for 91% of the responders (93% hepatogastroenterologists vs 88% pulmonologists; p = 0.27). An Ultrasound pleural scanning was systematically performed before a puncture for 43% of the responders (36% hepatogastroenterologists vs 70% pulmonologists; p
Published: 2023
Full Text: View/download PDF

2. Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case–control study

Author: Pierre Deltenre, Audrey Payancé, Laure Elkrief, Vincenzo La Mura, Florent Artru, Anna Baiges, Jean-Paul Cervoni, Louise China, Isabelle Colle, Elise Lemaitre, Bogdan Procopet, Dietmar Schiller, Christophe Bureau, Odile Goria, Isabelle Ollivier, Alexandre Nuzzo, Pierre-Emmanuel Rautou, and Aurélie Plessier
Subjects: Splanchnic vein thrombosis, Portal vein thrombosis, SARS-CoV-2 infection, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract: Background & Aims: Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a risk factor for splanchnic vein thrombosis (SVT) is unknown. This study aims to assess the impact of SARS-CoV-2 infection on the presentation and prognosis of recent SVT and to identify specific characteristics of SARS-CoV-2-associated SVT. Methods: This is a retrospective study collecting health-related data of 27 patients presenting with recent SVT in the context of SARS-CoV-2 infection in 12 Vascular Liver Disease Group (VALDIG) centres and in comparison with 494 patients with recent SVT before the SARS-CoV-2 pandemic. Results: Twenty-one patients with SARS-CoV-2 had portal vein thrombosis with or without thrombosis of another splanchnic vein, two had superior mesenteric vein thrombosis, one had splenic vein thrombosis, and three had hepatic vein thrombosis. Diagnosis of SVT was made 10 days (95% CI 0–24 days) after the diagnosis of SARS-CoV-2 infection. Fever (52 vs. 15%; p
Published: 2023
Full Text: View/download PDF

3. XIVes Journées nationales provinciales de dermatologie, Rennes, 30 juin-2 juillet 2022 – Extraits III. Enquête sur la télémédecine et la démographie des dermatologues libéraux en Bretagne en février 2022

Author: Nicole Cochelin, Isabelle Le Hir-Garreau, Cécile Chabbert, and Isabelle Ollivier
Published: 2023
Full Text: View/download PDF

4. Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications

Author: Aurélie Plessier, Marina Esposito‐Farèse, Anna Baiges, Akash Shukla, Juan Carlos Garcia Pagan, Emmanuelle De Raucourt, Isabelle Ollivier‐Hourmand, Jean‐Paul Cervoni, Victor De Ledinghen, Zoubida Tazi, Jean‐Baptiste Nousbaum, René Bun, Christophe Bureau, Christine Silvain, Olivier Tournilhac, Mathieu Gerfaud‐Valentin, François Durand, Odile Goria, Luis Tellez, Agustin Albillos, Stefania Gioia, Oliviero Riggio, Andrea De Gottardi, Audrey Payance, Pierre‐Emmanuel Rautou, Louis Terriou, Aude Charbonnier, Laure Elkrief, Regis Peffault de la Tour, Dominique‐Charles Valla, Nathalie Gault, and Flore Sicre de Fontbrune
Subjects: Adult, Male, Liver Diseases, Hemoglobinuria, Paroxysmal, Humans, Female, Thrombosis, Hematology, Antibodies, Monoclonal, Humanized, Retrospective Studies
Abstract: A total of 2%-10% of patients with vascular liver disease (VLD) have paroxysmal nocturnal hemoglobinuria (PNH). Eculizumab reduces complement-mediated haemolytic activity in PNH. This study was aimed at assessing the impact of eculizumab on VLD outcome. Retrospective cohort of PNH patients, in Valdig registry, who had VLD diagnosed between 1997 and 2019 is considered. Eculizumab was the exposure of interest. Studied outcomes were death, venous thrombosis, bleeding, arterial ischemic event, infection, and liver-related complications. We compared survival and new thrombotic events from PNH/VLD cohort to Envie2 non-PNH cohort. Sixty-two patients (33 women), median age 35 years (28-48) and median follow-up VLD diagnosis 4.7 years (1.2-9.5), were included. Clone size was 80% (70-90), median hemoglobin concentration was 10.0 g/dl (8-11), and lactate dehydrogenase (LDH) was 736 IU (482-1744). Forty-two patients (68%) had eculizumab; median exposure time was 40.1 [9.3-72.6] months. Mortality was significantly lower in exposed versus nonexposed period: 2.6 versus 8.7 per 100 (PY), incidence rate ratio (IRR) was 0.29, 95% CI (0.1-0.9), p = .035. Thrombosis recurrence occurred less frequently during the exposure to eculizumab: 0.5 versus 2.8 per 100 PY, IRR 0.22 (0.07-0.64). Other secondary end points (i.e., bleeding, arterial ischemic lesions, infection, and liver complications) were less common during the exposure to eculizumab, although not reaching statistical significance. Six-year thrombosis-free survival was 70%, 95% CI [0.60-0.83] for PNH cohort and 83%, 95% CI [0.70-1.00] for non-PNH Envie 2 patients, (p .001). In conclusion, patients with PNH and VLD are at higher risk of recurrent thrombosis than non-PNH patients. Eculizumab is significantly associated with a lower mortality and less thrombotic recurrence in patients with PNH and VLD.
Published: 2022
Full Text: View/download PDF

5. Germline Mutations of Telomere-Related Genes are a Major Risk Factor for Liver Disease: A Multicentric Transversal Study

Author: Sabrina Sidali, Raphaël Borie, Flore Sicre de Fontbrune, Kinan El Husseini, Pierre-Emmanuel Rautou, Elodie Lainey, Odile Goria, Bruno Crestani, Jacques Cadranel, Vincent Cottin, Vincent Bunel, Jérôme Dumortier, Emmanuel Jacquemin, Noémi Reboux, Sandrine Hirschi, Arnaud Bourdin, Magdalena Meszaros, Sébastien Dharancy, Sophie Hilaire, Vincent Mallet, Martine Reynaud-Gaubert, Louis Terriou, Frédéric Gottrand, Wadih Abou Chahla, Jean-Emmanuel Kahn, Paul Carrier, Faouzi Saliba, Laura Rubbia-Brandt, John-David Aubert, Laure Elkrief, Victor de Ledinghen, Armand Abergel, Olivier Tournilhac, Pauline Houssel, Stéphane Jouneau, Ludivine Wemeau, Anne Bergeron, Thierry Leblanc, Isabelle Ollivier-Hourmand, Eric Nguyen-Khac, Hélène Morisse-Pradier, Ibrahima Ba, Catherine Boileau, Françoise Roulot-Thoraval, Valérie Vilgrain, Christophe Bureau, Hilario Nunes, Jean-Marc Naccache, François Durand, Claire Francoz, Dominique Roulot, Dominique-Charles Valla, Valérie Paradis, Caroline Kannengiesser, and Aurélie Plessier
Published: 2023
Full Text: View/download PDF

6. Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis

Author: Aurélie Plessier, Odile Goria, Jean Paul Cervoni, Isabelle Ollivier, Christophe Bureau, Armelle Poujol-Robert, Anne Minello, Pauline Houssel-Debry, Pierre Emmanuel Rautou, Audrey Payancé, Giovanna Scoazec, Onorina Bruno, Michele Corbic, Francois Durand, Valérie Vilgrain, Valérie Paradis, Larbi Boudaoud, Emmanuelle de Raucourt, Carine Roy, Nathalie Gault, and Dominique Valla
Published: 2022
Full Text: View/download PDF

7. Chronic hepatic involvement in the clinical spectrum of A20 haploinsufficiency

Author: Nicolas Martin Silva, Hubert de Boysson, Sophie Georgin-Lavialle, Samuel Deshayes, A. Dumont, Elma El Khouri, Achille Aouba, Serge Amselem, Isabelle Ollivier, Irina Giurgea, Isabelle Koné-Paut, Céline Bazille, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU), Sorbonne Université (SU), Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), UF de Génétique moléculaire [CHU Trousseau], CHU Trousseau [APHP], and Couvet, Sandrine
Subjects: Liver Cirrhosis, Heterozygote, medicine.medical_specialty, Anti-nuclear antibody, [SDV]Life Sciences [q-bio], Folliculitis, Haploinsufficiency, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, Gastroenterology, Young Adult, 03 medical and health sciences, Pernicious anaemia, Pericarditis, 0302 clinical medicine, oral and genital aphthosis, Internal medicine, Humans, Medicine, hepatic fibrosis, A20 haploinsufficiency, TNFAIP3, Aged, Retrospective Studies, Autoimmune disease, Hepatology, business.industry, NF-kappa B, medicine.disease, Pustulosis, [SDV] Life Sciences [q-bio], [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, medicine.symptom, business, Hepatic fibrosis
Abstract: International audience; Background & aims: Secondary to tumour necrosis factor-alpha induced protein 3 (TNFAIP3) mutations, A20 haploinsufficiency (HA20) is a recently described autoinflammatory disease with clinical features similar to those of Behçet's and Crohn's diseases but with a constantly expanding clinical spectrum. Here, we describe HA20 liver involvement in three new patients from the same family.Methods: We retrospectively assessed clinical, biological and/or histological findings for eight patients over three generations of the same family with heterozygous mutations in the TNFAIP3 gene (c.259C > T, p.Arg87*).Results: The eight patients exhibited the following: aphthous ulcers (8/8, bipolar in 7), autoimmune features (6/8, including 5 with definitive autoimmune disease diagnoses, ie, type I diabetes, Hashimoto thyroiditis, pernicious anaemia, and/or 5 with antinuclear antibodies ≥320), pustulosis/folliculitis (5/8), abdominal pain (4/8), arthralgia (3/8), enlarged cervical lymph nodes (3/8) and pericarditis (1/8). In addition, three patients (twin sisters and their grandmother aged 23 and 70 years, respectively) exhibited persistent mild hepatic cytolysis associated with splenomegaly (n = 3), hepatomegaly (n = 1) and/or liver atrophy (n = 1) on echography. We could not detect any other causes of chronic liver diseases. Liver biopsies from three patients displayed hepatic fibrosis, hepatocyte injury and/or CD4+ /CD8+ T lymphocyte infiltration, and patterns of inflammatory cells and NLRP3 or NF-κB immunostaining differed from the predominant neutrophil infiltration observed in skin or some digestive tract biopsies.Conclusions: This study reinforces the dual involvement of innate and adaptive immunity in HA20 according to both acute and chronic injury and the organ involved and widens its clinical spectrum to include chronic hepatic involvement.
Published: 2021
Full Text: View/download PDF

8. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score

Author: Olivier Chazouillères, Florent Artru, Eleonora De Martin, Philippe Mathurin, Camille Besch, Christophe Duvoux, François Durand, Odile Goria, Hélène Fontaine, Hélène Agostini, Isabelle Ollivier-Hourmand, Noemi Reboux, Olivier Roux, Filomena Conti, Nathalie Ganne-Carrié, Didier Samuel, Georges-Philippe Pageaux, Philippe Ichai, Marilyne Debette-Gratien, Christine Silvain, Alexandra Heurgue, Jean-Marie Peron, Sylvie Radenne, Jérôme Dumortier, Audrey Coilly, Pauline Houssel-Debry, Sandrine Barge, Marc Bourlière, Pascal Potier, Jean-Charles Duclos-Vallée, Vincent Di Martino, Mylène Sebagh, and Victor de Ledinghen
Subjects: 0301 basic medicine, medicine.medical_specialty, Multivariate analysis, Hepatology, medicine.drug_class, Bilirubin, business.industry, medicine.medical_treatment, Odds ratio, Autoimmune hepatitis, Liver transplantation, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, chemistry, Internal medicine, medicine, Corticosteroid, 030211 gastroenterology & hepatology, Prospective cohort study, business, Survival rate
Abstract: Background & Aims In acute severe autoimmune hepatitis (AS-AIH), the optimal timing for liver transplantation (LT) remains controversial. The objectives of this study were to determine early predictive factors for a non-response to corticosteroids and to propose a score to identify patients in whom LT is urgently indicated. Methods This was a retrospective, multicenter study (2009-2016). A diagnosis of AS-AIH was based on: i) Definite or probable AIH based on the simplified IAIHG score; ii) international normalized ratio (INR) ≥1.5 and/or bilirubin >200 μmol/L; iii) No previous history of AIH; iv) Histologically proven AIH. A treatment response was defined as LT-free survival at 90 days. The evolution of variables from corticosteroid initiation (day-D0) to D3 was estimated from: Δ%3 = (D3–D0)/D0. Results A total of 128 patients were included, with a median age of 52 (39–62) years; 72% were female. Overall survival reached 88%. One hundred and fifteen (90%) patients received corticosteroids, with a LT-free survival rate of 66% at 90 days. Under multivariate analysis, D0-INR (odds ratio [OR] 6.85; 95% CI 2.23–21.06; p Conclusion In patients with AS-AIH, INR at the introduction of corticosteroids and the evolution of INR and bilirubin are predictive of LT or death. Within 3 days of initiating corticosteroids, the SURFASA score can identify non-responders who require a referral for LT. This score needs to be validated in a prospective cohort. Lay summary The management of patients with acute severe autoimmune hepatitis is highly challenging, particularly regarding their early referral for liver transplantation. We found that international normalized ratio at the initiation of corticosteroid therapy and the evolution of international normalized ratio and bilirubin values after 3 days of therapy were highly predictive of liver transplantation or death. We are thus proposing a score that combines these variables and identifies patients in whom liver transplantation is urgently required.
Published: 2021
Full Text: View/download PDF

9. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice

Author: Aubé, Christophe, Oberti, Frédéric, Lonjon, Julie, Pageaux, Georges, Seror, Olivier, NʼKontchou, Giséle, Rode, Agnes, Radenne, Sylvie, Cassinotto, Christophe, Vergniol, Julien, Bricault, Ivan, Leroy, Vincent, Ronot, Maxime, Castera, Laurent, Michalak, Sophie, Esvan, Maxime, Vilgrain, Valérie, Tasu, Jean Pierre, Sylvain, Christine, Luciani, Alain, Duvoux, Christophe, Pilleul, Frank, Dumortier, Jérôme, Baudin, Guillaume, Anty, Rodolphe, Chevallier, Patrick, Le Pennec, Vincent, Hourmand, Isabelle Ollivier, Estivalet, Louis, Minello, Anne, Frampas, Eric, Archambeaud, Isabelle, Guillygomarc’h, Anne, Brun, Vanessa, Gandon, Yves, Cuilleron, Muriel, Patouillard, Brigitte, Guiu, Boris, Gallix, Benoit, and Lebigot, Jérôme
Published: 2017
Full Text: View/download PDF

10. Social and medical support initiatives in vascular liver diseases in France, from child to adult

Author: Virginia Hernández-Gea, Odile Goria, Danielle Dutheil, Dominique Debray, Julie Devictor, Anne Leclercq, Maxime Gasperment, Emilie Le Beux, Corinne Brault, Rautou Pierre Emmanuel, Isabelle Ollivier-Hourmand, and Plessier Aurélie
Subjects: medicine.medical_specialty, Hepatology, business.industry, Liver Diseases, Gastroenterology, Social Support, Medical support, Social support, Liver, Family medicine, Therapeutic patient education, Practice Guidelines as Topic, medicine, Psychological support, Humans, France, Vascular Diseases, business
Published: 2020
Full Text: View/download PDF

11. Malnutrition in patients with cirrhosis: Screen or treat?

Author: Isabelle Ollivier-Hourmand, Florence Vasseur, Benoît Dupont, and Marie-Astrid Piquet
Subjects: Liver Cirrhosis, Pediatrics, medicine.medical_specialty, Nutrition and Dietetics, Cirrhosis, Nutrition assessment, business.industry, Malnutrition, MEDLINE, Nutritional Status, Medicine (miscellaneous), Nutritional status, medicine.disease, Nutrition Assessment, medicine, Humans, In patient, business
Published: 2021
Full Text: View/download PDF

12. Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial

Author: Philippe Merle, Mohamed Bouattour, Jean-Frédéric Blanc, Jean-Marie Peron, Marilyne Debette-Gratien, Pierre Nahon, Eric Nguyen-Khac, Jean Marc Phelip, Eric Assenat, Vincent Bourgeois, Carine Richou, Alexandra Heurgue, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Thomas Uguen, Stéphane Cattan, Sylvie Thevenon, Camille Boucheny, and Pierre Pradat
Subjects: Cancer Research, Oncology
Abstract: 573 Background: CABO is approved in second (2L) or third line (3L) systemic therapy for pts with advanced HCC after SOR failure, based on results of the CELESTIAL phase 3. CLERANCE was designed to evaluate safety and efficacy of CABO in pts with HCC in real-world practice in a French population. Methods: This prospective, French multicentre (n=17), interventional study aims to recruit 110 pts with unresectable HCC when a decision of CABO treatment was made in 2L or 3L after prior sorafenib (SOR) failure, according to the French health authority approved label. The primary endpoint is the incidence of treatment-related adverse events (TRAE) of grade > 2 (NCI-CTCAE v5) by a central review committee. Secondary endpoints include overall survival (OS), objective response rate (ORR) (RECIST v1.1 per investigator assessed), progression-free survival (PFS), time to progression (TTP) and profiles of CABO administration. Results: Of 110 pts enrolled, the final analysis focused on the 99 pts who starting CABO (11 pts withdrawn due to screen failure) and followed up to 12 mo (data cut-off: November 8, 2021). Pts were mainly males (89%), 69 years median age (range 24-85), Child-Pugh A (94.9%) / B7 (5.1%), and ALBI score-1 (33%), 2 (60%), 3 (5%), not evaluated (NE) (2%). About 59% pts received CABO in 2L after SOR, whereas 41% were in 3L after SOR and another line (TKI or IO). SOR was discontinued due to tumor progression (68%) or intolerance (32%) with a median duration of 4.2 mo (95% CI 3.5-4.8) and a median dose of 800 mg (95% CI 631-800). In the 99 pts starting CABO, 128 treatment-emergent adverse events (TEAE) of grade > 2 were reported, 40 of them classified as TRAE: hand foot skin reaction (14%), diarrhea (11%), asthenia and/or anorexia and/or weight loss (12%), arterial hypertension (4%). The ORR was 7% with 58% of disease control rate (DCR). Median PFS was 6.2 mo (95% CI, 5.3-8.7), TTP 8.2 mo (95% CI 6.1-12.8), without any difference when CABO used in 2L or 3L line (with prior IO [11%] or not). OS was 11.5 mo (95% CI 9.2-14.6) since start of CABO and 23 mo (95% CI 17.3-29.4) since the first systemic line. ALBI score at 1 was an independent marker of better OS in multivariate analysis (Exp[b] 3.26, 95% CI 1.86-5.69, p
Published: 2023
Full Text: View/download PDF

13. Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma

Author: Isabelle Ollivier-Hourmand, Manon Allaire, Jean Paul Cervoni, Delphine Weil, Violaine Ozenne, Pierre Emmanuel Rautou, Charlotte Bouzbib, Sabrina Sidali, Frédéric Oberti, Maeva Guillaume, Paul Castellani, Paul Calame, Sandrine Barge, and Christophe Bureau
Subjects: Hepatology
Published: 2022
Full Text: View/download PDF

14. New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination-a vascular liver disease group (VALDIG) initiative

Author: Raoel Maan, Aurélie Plessier, Louise China, David Patch, Anna Baiges, Juan Carlos Garcia Pagan, Virginia Hernandez-Gea, Marie-Noëlle Hilleret, E.T.T.L. Tjwa, Ilias Kounis, Christophe Bureau, Baptiste Giguet, Alexandra Heurgue-Berlot, Isabelle Ollivier-Hourmand, Xavier Causse, Filipe Gaio Castro Nery, Mandy Lauw, and Sarwa Darwish Murad
Subjects: Hepatology
Published: 2022
Full Text: View/download PDF

15. Recurrence of primary sclerosing cholangitis after liver transplantation: a french cohort study including 571 patients

Author: Florian Veyre, Eleonora De Martin, Domitille Erard, Claire Francoz, Laure Elkrief, Camille Besch, Olivier Boillot, Karim Boudjema, Filomena Conti, Sebastien Dharancy, Christophe Duvoux, Jean Gugenheim, Jean Hardwigsen, Marie-Noëlle Hilleret, Isabelle Ollivier-Hourmand, Maryline Debette-Gratien, Pauline Houssel-Debry, Nassim Kamar, Jean-Baptiste Hiriart, Stéphanie Faure, Faouzi Saliba, Didier Samuel, Claire Vanlemmens, Christophe Corpechot, Olivier Chazouillères, and Jérôme Dumortier
Subjects: Hepatology
Published: 2022
Full Text: View/download PDF

16. Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients

Author: Philippe Halfon, Ramuntcho Arotcarena, Isabelle Rosa-Hézode, Damien Lucidarme, Jean-François Cadranel, Christophe Renou, André-Jean Remy, Ratmony Heng, Mourad Medmoun, Isabelle Ollivier-Hourmand, Armand Garioud, Xavier Causse, Honore Zougmore, Camelia Mokhtari, Xavier Amiot, Alexandre Pariente, Philippe Pulwermacher, and David Zanditenas
Subjects: Adult, Male, medicine.medical_specialty, Multivariate analysis, Sofosbuvir, Hepatitis C virus, medicine.disease_cause, Antiviral Agents, Gastroenterology, Drug Administration Schedule, Polyethylene Glycols, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Ribavirin, Ascites, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Aged, Aged, 80 and over, Hepatology, business.industry, Interferon-alpha, Odds ratio, Hepatitis C, Chronic, Middle Aged, Viral Load, Recombinant Proteins, 3. Good health, Treatment Outcome, chemistry, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, France, medicine.symptom, business, Viral load, Cohort study, medicine.drug
Abstract: Introduction Sofosbuvir is the first directly-acting antiviral for the treatment of hepatitis C virus. First, the regimens were combinations with sofosbuvir+ribavirin (SR) or with sofosbuvir+ribavirin and pegylated-interferon α-2a (SPR) with cure rates around 90%. The aim of this study was to report the results of these combinations in 'real-life' in France. Materials and methods Main features of patients treated with SR or SPR in 24 hospitals were collected. Undetectable hepatitis C virus week 12 viral load after treatment defined sustained virological response (SVR12). Statistics were performed using StatView software for descriptive analysis and χ for the sub-groups comparisons. Results Two hundred and eleven patients were analyzed. The average age was 56.1. One hundred and seventy-one (89%) patients had a fibrosis score of at least 3. Seventy-nine patients were infected by a genotype 1 (G1). One hundred and thirteen patients were treated with SR and 95 with SPR. In naive patients: with SPR for 12 weeks, SVR12 was 93% in G1, 100% in G3 and 83% in G4. With SR for 12 weeks, SVR12 was 100% in G2 patients (6/6). The safety of these regimens was satisfactory with only two patients who had to stop P due to severe side effects. Multivariate analysis shows a higher SVR in SPR versus SR (odds ratio = 1.28; P = 0.05) and in G2 or G3 versus others (odds ratio = 1.56; P = 0.04). Moreover, Child-Pugh score B or C (P = 0.02), platelets count under 100G/l (P = 0.05) or a past event of ascites (P = 0.04) was independently associated with less SVR. Conclusion This multicenter large study confirms the good results of SR for 12 weeks in G2 naive patients. Finally, a decompensated cirrhosis, a past event of ascites and a baseline low platelet count were strongly associated with poor response.
Published: 2019
Full Text: View/download PDF

17. Non-invasive diagnosis and follow-up of vascular liver diseases

Author: Isabelle Ollivier-Hourmand, Christophe Bureau, Marie Decraecker, Aurélie Plessier, Nathalie Ganne-Carrié, Valérie Vilgrain, M. Bourlière, Maxime Ronot, Laure Elkrief, Pierre-Emmanuel Rautou, Victor de Lédinghen, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de référence des Maladies Vasculaires du Foie [Paris] (FILFOIE), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Saint-Joseph [Marseille], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Avicenne [AP-HP], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), École pratique des hautes études (EPHE), and Malbec, Odile
Subjects: Liver Cirrhosis, medicine.medical_specialty, Hepatology, medicine.diagnostic_test, business.industry, [SDV]Life Sciences [q-bio], Biopsy, Liver Diseases, Non invasive, Gastroenterology, MEDLINE, [SDV] Life Sciences [q-bio], Liver, Liver biopsy, Medicine, Elasticity Imaging Techniques, Humans, Radiology, Abnormality, business, Follow-Up Studies
Abstract: International audience; Vascular disorders of the liver are rare diseases, some of which are diagnosed mainly with non-invasive tests and others by liver biopsy. Non-invasive methods can be used to diagnose and monitor these diseases. However, their evaluation needs to be performed by expert centers. Liver biopsy is needed each time there is an unexplained abnormality.
Published: 2021
Full Text: View/download PDF

18. IgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients

Author: Ines Elhani, Evangeline Pillebout, Antoine Hankard, Matthieu Groh, Sophie Greillier, Benjamin Terrier, François Vrtovsnik, Adrien Bigot, Noémie Jourde-Chiche, Hubert de Boysson, Loic Raffray, Alexandra Audemard-Verger, Geoffrey Urbanski, Isabelle Ollivier, Achille Aouba, Georges-Philippe Pageaux, Nabil Belfeki, François Maillot, Service de rhumatologie, CHU Bordeaux [Bordeaux], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Foch [Suresnes], CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Adult, Liver Cirrhosis, Vasculitis, 0301 basic medicine, medicine.medical_specialty, Cirrhosis, Henoch-Schonlein purpura, Immunology, Alcohol abuse, Autoimmune hepatitis, liver, Gastroenterology, 03 medical and health sciences, Liver disease, IgA vasculitis, 0302 clinical medicine, Rheumatology, Internal medicine, medicine, Humans, Immunology and Allergy, Aged, Retrospective Studies, business.industry, cirrhosis, Middle Aged, medicine.disease, Immunoglobulin A, 3. Good health, 030104 developmental biology, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Female, 030211 gastroenterology & hepatology, alcohol, Viral hepatitis, business
Abstract: ObjectiveImmunoglobulin A vasculitis (IgAV) and nephropathy (IgAN) share common immunological mechanisms. Liver cirrhosis is well known to be associated with IgAN. Here, we aimed to describe the presentation and outcome of IgAV patients with underlying cirrhosis.MethodsWe conducted a French nationwide retrospective study of adult patients presenting with both IgAV and cirrhosis. Baseline characteristics were compared to those of the 260 patients included in the French nationwide IgAV registry (IGAVAS).ResultsTwenty patients were included, and 7 (35%) were female. The mean ± SD age was 62.7 ± 11 years. At baseline, compared with IGAVAS patients, patients with underlying cirrhosis were older (62.7 ± 11 vs 50.1 ± 18, P < 0.01) and displayed more constitutional symptoms (weight loss 25% vs 8%, P = 0.03). Patients with underlying cirrhosis were also more likely to exhibit elevated serum IgA levels (5.6 g/L vs 3.6 g/L, P = 0.02). Cirrhosis and IgAV were diagnosed simultaneously in 12 patients (60%). Cirrhosis was mainly related to alcohol intake (n = 15, 75%), followed by nonalcoholic steato-hepatitis (n = 2), chronic viral hepatitis (n = 1), hemochromatosis (n = 1), and autoimmune hepatitis (n = 1). During follow-up with a median of 17 months (IQR 12–84), 10/13 (77%) exhibited IgAV remission at Month 3. One patient presented a minor relapse. Six patients died, but no deaths were related to IgAV.ConclusionWe report the first case series of IgAV patients with underlining cirrhosis, to our knowledge, which was mainly alcohol related. The liver disease did not seem to affect baseline vasculitis characteristics. Physicians should investigate the existence of liver cirrhosis at IgAV diagnosis, especially in the context of alcohol abuse.
Published: 2021
Full Text: View/download PDF

19. Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding

Author: Charlotte Bouzbib, Olivier Sutter, Juan Carlos García-Pagán, Jean-Marie Péron, Vincent Le Pennec, Christophe Bureau, Nathalie Ganne-Carrié, Maxime Mallet, Dominique Thabut, Pol Olivas, Anna Baiges, Hélène Larrue, Thong Dao, Lucile Moga, Eric Trepo, Virginia Hernández-Gea, Aurélie Walter, Isabelle Ollivier-Hourmand, Marika Rudler, J.-C. Nault, Manon Allaire, and Marie Angèle Robic
Subjects: Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, Organ Dysfunction Scores, medicine.medical_treatment, Esophageal and Gastric Varices, Gastroenterology, End Stage Liver Disease, Liver disease, Model for End-Stage Liver Disease, Predictive Value of Tests, Internal medicine, Hypertension, Portal, medicine, Humans, Lactic Acid, Survival rate, Salvage Therapy, Hepatology, business.industry, Middle Aged, medicine.disease, Prognosis, Survival Analysis, Exact test, Spain, Cohort, Portal hypertension, Female, France, Portasystemic Shunt, Transjugular Intrahepatic, business, Gastrointestinal Hemorrhage, Transjugular intrahepatic portosystemic shunt, Biomarkers
Abstract: BACKGROUND AND AIMS Data about the prognosis of salvage transjugular intrahepatic portosystemic shunt (TIPS) using covered stents for refractory variceal bleeding caused by portal hypertension are scarce. We aimed to assess survival and to identify predictors of mortality in these patients. APPROACH AND RESULTS One hundred sixty-four patients with cirrhosis from five centers treated with salvage TIPS between 2007 and 2017 were retrospectively divided into a derivation cohort (83 patients) and a validation cohort (81 patients). Comparisons were performed using the Mann-Whitney and Fischer's exact test. Six-week overall survival (OS) was correlated with variables on the day of the TIPS using Kaplan-Meier curves with log-rank test and univariate/multivariate analyses using the Cox model. Eighty-three patients were included in the derivation cohort (male, 78%; age, 55 years, alcohol-associated cirrhosis, 88%; Model for End-Stage Liver Disease [MELD], 19 [15-27]; arterial lactate, 3.7 mmol/L [2.0-8.3]). Six-week OS rate was 58%. At multivariate analysis, the MELD score (OR, 1.064; 95% CI, 1.005-1.126; P = 0.028) and arterial lactate (OR, 1.063; 95% CI, 1.013-1.114; P = 0.032) were associated with 6-week OS. Six-week OS rates were 100% in patients with arterial lactate ≤2.5 mmol/L and MELD score ≤ 15 and 5% in patients with lactate ≥12 mmol/L and/or MELD score ≥ 30. The 81 patients of the validation cohort had similar MELD and arterial lactate level but lower creatinine level (94 vs 106 µmol/L, P = 0.008); 6-week OS was 67%. Six-week OS rates were 86% in patients with arterial lactate ≤2.5 mmol/L and MELD score ≤ 15 and 10% for patients with lactate ≥12 mmol/L and/or MELD score ≥ 30. In the overall cohort, rebleeding rate was 15.8% at 6 weeks, and the acute-on-chronic liver failure grade (OR, 1.699; 95% CI, 1.056-1.663; P = 0.040) was independently associated with rebleeding. CONCLUSIONS After salvage TIPS, 6-week mortality remains high and can be predicted by MELD score and lactate. Survival rate at 6 weeks was >85% in patients with arterial lactate ≤2.5 mmol/L and MELD score ≤ 15, while mortality was >90% for lactate ≥12 mmol/L and/or MELD score ≥ 30.
Published: 2021

20. Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide

Author: Victor de Lédinghen, Paul Hermabessière, Sophie Metivier, Edouard Bardou-Jacquet, Marie-Noelle Hilleret, Veronique Loustaud-Ratti, Nathalie Ganne-Carrié, Laurent Alric, Isabelle Fouchard Hubert, Louis d’Alteroche, Bruno Roche, Fabien Zoulim, Anne Gervais, Helene Fontaine, Anne Minello Franza, Christiane Stern, Jérôme Dumortier, Dominique Roulot, Xavier Causse, Isabelle Ollivier-Hourmand, Karine Lacombe, Patrick Miailhes, Frederic Heluwaert, Leon Muti, Isabelle Rosa, Valérie Canva, Damien Lucidarme, Dominique Larrey, Bernard Prouvost-Keller, Caroline Lascoux-Combe, and Juliette Foucher
Subjects: Hepatology
Published: 2022
Full Text: View/download PDF

21. Hepatitis B Virus Reactivation Under Treatment with Ibrutinib, A Known and Still Dangerous Entity: A Clinical Case Description

Author: Justine Adnet, Emilie Reboursiere, Bertille Comoz, Louise Lebedel, Charlotte Orhan, Astrid Vabret, Isabelle Ollivier-Hourmand, and Julia Din
Published: 2021
Full Text: View/download PDF

22. Treatment of hidradenitis suppurativa using a long-pulsed hair removal neodymium:yttrium-aluminium-garnet laser: A multicenter, prospective, randomized, intraindividual, comparative trial

Author: Cyril Maire, Nathalie Gral, Sabrina Fourcade, S. Lagrange, Anne Marie Collet Vilette, Anne Le Pillouer-Prost, Isabelle Ollivier, Amandine Servy, Annabel Maruani, Michael Naouri, Dominique Boineau, Hugues Cartier, Olivier Cogrel, Regine Bousquet Rouaud, G. Toubel, Thierry Passeron, Yvon Perrillat, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Centre de Référence des Epidermolyses Bulleuses Héréditaires [Nice] (CREBHN), Centre Hospitalier Universitaire de Nice (CHU Nice), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
Subjects: medicine.medical_specialty, [SDV]Life Sciences [q-bio], Pain, chemistry.chemical_element, Lasers, Solid-State, Dermatology, Hair Removal, Neodymium, law.invention, 030207 dermatology & venereal diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Yttrium aluminium garnet, law, Hair removal, Humans, Medicine, Single-Blind Method, Hidradenitis suppurativa, Prospective Studies, ComputingMilieux_MISCELLANEOUS, business.industry, Comparative trial, Symptom Flare Up, medicine.disease, Laser, Hidradenitis Suppurativa, 3. Good health, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, business
Abstract: International audience
Published: 2021
Full Text: View/download PDF

23. International French-speaking multicentre practice survey on hepatic hydrothorax (HH) : Results of the 'Hep Hep' study among 529 hepatogastroenterologist (HG) or pneumologist (PN) respondents

Author: Nathalie Ganne-Carrié, Eric Nguyen-Khac, Laure Elkrief, Isabelle Ollivier, Jean-Baptiste Nousbaum, Chantal Raherison, Marc Bourlière, Jean-François Cadranel, Véronique Loustaud-Ratti, Christophe Bureau, Xavier Causse, Manon Allaire, Jean-Marie Péron, Philippe Sogni, Bernard Maitre, Thong Dao, Bertrand Hanslik, Tristan Le Magoarou, Thierry Thevenot, Cadranel Jacques, Groupe Hospitalier Public du Sud de l'Oise [Creil] (GHPSO), Theranoscan [CHU Tenon] (GRC 4), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de Pneumologie = Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Hépatologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale (SPURBO), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Centre Hospitalier Régional d'Orléans (CHRO), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Saint-Joseph [Marseille], Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC] (FunGeST), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: medicine.medical_specialty, Hepatic hydrothorax, business.industry, Internal medicine, [SDV]Life Sciences [q-bio], Medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2021
Full Text: View/download PDF

24. Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review

Author: Jean-François Cadranel, Thi Thu Nga Nguyen, Honore Zougmore, Isabelle Ollivier-Hourmand, Armand Garioud, Ratmony Heng, Thong Dao, Manon Allaire, Claire Perignon, Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)
Subjects: Liver Cirrhosis, Methicillin-Resistant Staphylococcus aureus, medicine.medical_specialty, Antifungal Agents, Delayed Diagnosis, Cirrhosis, medicine.drug_class, Gram-positive bacteria, [SDV]Life Sciences [q-bio], Antibiotics, Cephalosporin, Context (language use), Gram-Positive Bacteria, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Antibiotic resistance, Albumins, Drug Resistance, Multiple, Bacterial, Humans, Medicine, Intensive care medicine, Gram-Positive Bacterial Infections, Hepatology, biology, business.industry, Mortality rate, Gastroenterology, Acute-On-Chronic Liver Failure, Ascites, Candidemia, Vancomycin Resistance, Bacterial Infections, medicine.disease, biology.organism_classification, 3. Good health, Mycoses, Staphylococcus aureus, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, business, Enterococcus
Abstract: Patients with cirrhosis are prone to develop bacterial infections, which consist in one of the major precursors of Acute-on-Chronic Liver Failure (ACLF) and are responsible for a high mortality rate. In recent years, the management of bacterial infections in patients with cirrhosis has become increasingly complicated due to a change in bacterial ecology associated with a higher rate of cocci gram positive bacteria in Europe and America along with the emergence of a multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria leading to a decrease in the efficacy of empirical strategies based on the administration of third-generation cephalosporins. MDR and XDR now account for about 40% of the infections worldwide, and up to 70% in India. Among them, the most common ones are extended-spectrum beta-lactamase producing (ESBL-P) bacteria, carbapenem-resistant enterobacteriaceae (CRE), Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant enterococci (VRE). An early diagnosis associated to an empirical antibiotic adapted to the site of infection and potential bacterial resistance is now crucial in order to improve the chances of survival and contain the resistance phenomenon. Moreover, a fungal infection must always be discussed in these high-risks patients, especially in the absence of clinical improvement under appropriate antibiotic treatment. In this review, we will focus on the emerging threat of MDR and XDR organisms, as well as fungal infections, in order to better adapt the therapeutic management of cirrhotic patients with infections.
Published: 2020
Full Text: View/download PDF

25. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

Author: Christophe Bureau, Bruno Cassinat, Juliette Soret-Dulphy, Odile Goria, Aurélie Plessier, Dominique Valla, Barbara Mora, Victor de Ledinghen, Nabih Maslah, Emmanuelle Verger, Stéphane Giraudier, Pierre-Emmanuel Rautou, Francesco Passamonti, Jean-Jacques Kiladjian, Claudia Siracusa, Pierre-Edouard Debureaux, and Isabelle Ollivier-Hourman
Subjects: Adult, Male, medicine.medical_specialty, Clinical Trials and Observations, Population, Polycythemia vera, Internal medicine, medicine, Humans, education, Myelofibrosis, Polycythemia Vera, Retrospective Studies, Venous Thrombosis, education.field_of_study, Acute leukemia, Myeloproliferative Disorders, business.industry, food and beverages, Retrospective cohort study, Hematology, Odds ratio, medicine.disease, Thrombosis, Primary Myelofibrosis, Cohort, Female, business
Abstract: Myeloproliferative neoplasms (MPNs) are the most frequent underlying causes of splanchnic vein thromboses (SVTs). MPN patients with SVTs (MPN-SVT) often have a unique presentation including younger age, female predominance, and low Janus kinase 2 (JAK2) mutation allele burden. This study aimed at identifying risk factors for adverse hematologic outcomes in MPN-SVT patients. We performed a retrospective study of a fully characterized cohort of MPN-SVT patients. The primary outcome was the incidence of evolution to myelofibrosis, acute leukemia, or death. Eighty patients were included in the testing cohort. Median follow-up was 11 years. Most of the patients were women with a mean age of 42 years and a diagnosis of polycythemia vera. The primary outcome was met in 13% of the patients and was associated with a JAK2V617F allele burden ≥50% (odds ratio [OR], 14.7) and presence of additional mutations in genes affecting chromatin/spliceosome (OR, 9). We identified high-risk patients (29% of the cohort) as those harboring at least 1 molecular risk factor: JAK2-mutant allele burden ≥50%, presence of chromatin/spliceosome/TP53 mutation. High-risk patients had worse event-free survival (81% vs 100%; P = .001) and overall survival at 10 years (89% vs 100%; P = .01) than low-risk patients. These results were confirmed in an independent validation cohort of 30 MPN-SVT patients. In conclusion, molecular profiling identified MPN-SVT patients with dismal outcome. In this high-risk population, a disease-modifying therapy should be taken into consideration to minimize the probability of transformation.
Published: 2020

26. Liste des collaborateurs

Author: Nelly, Achour-Frydman, primary, Olivier, Ami, additional, Françoise, Aubron, additional, Magalie, Barth, additional, Delphine, Beghin, additional, Claire, Bélanger, additional, Alexandra, Benachi, additional, Bernard, Benoit, additional, Guillaume, Benoist, additional, Florence, Biquard, additional, Dominique, Bonneau, additional, Claude, Bouderlique, additional, Pierre-Emmanuel, Bouet, additional, Françoise, Boussion, additional, Yves, Brossard, additional, Anne-Sophie, Cabaret, additional, Bruno, Carbonne, additional, Vanina, Castaigne, additional, Gihad, Chalouhi, additional, Paul, Chatel, additional, Bernard, Cimon, additional, Anne-Gaël, Cordier, additional, Valérie, Cormier-Daire, additional, Anne, Cortey, additional, Marie-Pierre, Cournot, additional, Évelyne, Cynober, additional, Albert, David, additional, Jocelyne, De Laveau-Coupet, additional, Benoît, Delorme, additional, Philippe, Descamps, additional, Alain, Diguet, additional, Julia, Dina, additional, Marc, Dommergues, additional, Guillaume, Ducarme, additional, Céline, Dupont-Bernabé, additional, Philippe, Duverger, additional, Sandra, El Sabbagh, additional, Élisabeth, Elefant, additional, René, Frydman, additional, Philippe, Gillard, additional, Stéphanie, Gouarin, additional, Liliane, Grangeot-Keros, additional, Agnès, Guichet, additional, Martine, Hérault, additional, Michel, Herlicoviez, additional, Véronique, Houfflin-Debarge, additional, Bertrand, Isidor, additional, François, Kotras, additional, Marc, Larsen, additional, Cédric, Le Caignec, additional, Martine, Le Merrer, additional, Magali, Leblanc, additional, Marc-David, Leclair, additional, Céline, Lefebvre-Lacœuille, additional, Catherine, Lépinard, additional, Ronaldo, Levy, additional, Didier, Loisel, additional, Dominique, Luton, additional, Laurent, Macchi, additional, Agnès, Mailloux, additional, Laurent, Mandelbrot, additional, Sylvie, Manouvrier-Hanu, additional, Anne-Élisabeth, Mas, additional, Marie-Caroline, Mas-Caradec, additional, Matthieu, Mezzadri, additional, Daniel, Moeglin, additional, Jean-Marc, Mouillie, additional, Isabelle, Ollivier, additional, Sophie, Patrier, additional, Philippe, Pézard, additional, Olivier, Picone, additional, Fabrice, Pierre, additional, Brigitte, Porcheron, additional, Patrice, Poulain, additional, Thierry, Rousseau, additional, Paul, Sagot, additional, Mariane, Saidi, additional, Loïc, Sentilhes, additional, Stéphane, Triau, additional, Christelle, Vauloup-Fellous, additional, Catherine, Vauzelle, additional, Éric, Verspyck, additional, Benjamin, Viaris De Lesegno, additional, Yves, Ville, additional, Edith, Vuillard, additional, Dominique, Weil, additional, and Norbert, Winer, additional
Published: 2011
Full Text: View/download PDF

27. MELALIB : Mélanomes cutanés, enquête prospective en dermatologie libérale

Author: Christian Derancourt, Alain Dupuy, Josefina Marco-Bonnet, Nicole Jouan, Elisabeth Lorier-Roy, Eric Tisserand, Florence Corgibet, Michel Le Maître, Isabelle Ollivier, Jean-Yves Gourhant, and J.-F. Sei
Subjects: Ocean Engineering, Safety, Risk, Reliability and Quality
Published: 2021
Full Text: View/download PDF

28. Liver involvement in patients with telomere-related genes mutations: prevalence, clinical, radiological, pathological features, outcome and risk factors

Author: Sabrina Sidali, Raphaël Borie, Sicre Flore, Elodie Lainey, Pierre-Emmanuel Rautou, Jacques Cadranel, Jean-marc Naccache, Vincent Cottin, Jérôme Dumortier, Emmanuel Jacquemin, Nousbaum Jean Baptiste, Sandrine Hirschi, Arnaud Bourdin, Magdalena Meszaros, Sebastien Dharancy, Sophie Hilaire, Vincent Mallet, Reynaud-Gaubert Martine, Louis Terriou, Frédéric Gottrand, Wadih Abou Chahla, Jean Emmanuel Khan, Paul Carrier, Faouzi Saliba, Laura Rubbia-Brandt, Laure Elkrief, Victor de Lédinghen, Armand Abergel, Tournilhac Olivier, Yasmina Chouik, Antoine Coupier, Thierry Leblanc, Isabelle Ollivier-Hourmand, Eric Nguyen Khac, Hélène Morisse-Pradier, Kinan El Husseini, Odile Goria, Ba Ibrahima, Dominique Roulot, Christophe Bureau, Hilario Nunes, Dominique Valla, Valérie Paradis, Kannengiesser Caroline, and Aurélie Plessier
Subjects: Hepatology
Published: 2020
Full Text: View/download PDF

29. Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS CO12 CirVir cohorts

Author: Isabelle Ollivier-Hourmand, Pierre Nahon, Cendrine Chaffaut, Thong Dao, Nga Nguyen, Marcellin Patrick, Dominique Roulot, Victor de Lédinghen, Stanislas Pol, Dominique Guyader, Isabelle Mabile-Archambeaud, Fabien Zoulim, Frédéric Oberti, Albert Tran, Jean-Pierre Bronowicki, Louis Dalteroche, Denis Ouzan, Jean Marie Peron, Jean-Pierre Zarski, Marc Bourliere, Dominique Larrey, Alexandre Louvet, Paul Cales, Armand Abergel, Philippe Mathurin, Ariane Mallat, Jean-Frédéric Blanc, Eric Nguyen Khac, Ghassan Riachi, Laurent Alric, Lawrence Serfaty, Tereza Antonini, Christophe Moreno, Pierre Attali, Dominique Thabut, Christophe Pilette, Jean Didier Grange, Christine Silvain, Nicolas Carbonell, Brigitte Bernard Chabert, Odile Goria, Claire Wartelle-Bladou, Romain Moirand, Christos Christidis, Gabriel Perlemuter, Violaine Ozenne, Jean Henrion, Sophie Hillaire, Vincent Di Martino, Xavier Amiot, Angela Sutton, Nathalie Barget, Yohann Repesse, Sylvie Chevret, and Nathalie Ganne-Carrié
Subjects: Hepatology
Published: 2020
Full Text: View/download PDF

30. Management of anticoagulation in adult patients with chronic parenchymal or vascular liver disease: Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver

Author: Isabelle, Ollivier-Hourmand, Nga, Nguyen, Andrea, De Gottardi, Dominique, Valla, Sophie, Hillaire, Danielle, Dutheil, Christophe, Bureau, Virginia, Hernandez-Gea, Emmanuelle, De Raucourt, and Aurélie, Plessier
Subjects: Liver, Liver Diseases, Chronic Disease, Anticoagulants, Humans, Thrombosis, Vascular Diseases
Published: 2020

31. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Author: Inmaculada Ales, Hakan Harputluoglu, Marc Peeters, Jean-Marc Phelip, G. Pelletier, Zsuzsanna Kahan, Alice Gangloff, Fadi Farhat, Imam Waked, Luc Lasser, René Gerolami, Giovanni Luca, Thomas Berg, Julie Le Boulicaut, Jean-Pierre Zarski, Ivan Borbath, Wolfgang Sieghart, Ozlem Ata, Howard Ozer, Julie Vincent, Thierry Fontanges, Bartomeu Massuti, Christos Galanopoulos, Mohammed El Kassas, Audrey Molé, Imam Wakid, Philippe Merle, Nasr El Lahlouby, Andreas Maieron, Marilyne Debette-Gratien, Antonio Cubillo, György Bodoky, Sylvain Manfredi, Faiza Khemissa-Akouz, Jawad Makarem, Jean-Frédéric Blanc, Ahmet Coker, Carmen Guillén, Massimo Colombo, Michael Schultheiß, Joerg Trojan, Yann Touchefeu, Isabelle Ollivier-Hourmand, François Habersetzer, Vlad Ratziu, Amr Abdel, Amr S Saad, Miguel Marín, Magdolna Dank, Mohamed Bouattour, Hélène Regnault, Jean-Didier Grangé, Pierluigi Toniutto, Hanaa Kohail, Sameh Shamaa, Carine Richou, Erdem Goker, Eric Nguyen-Khac, Oscar Alabiso, G.-P. Pageaux, Andrea Casadei-Gardini, Moses Raj, Alexander Zipprich, Henning Wege, Ilkay Tugba, Aurore Baron, Victor Navarro, Domenico Amoroso, Issam Chehade, Nashat Gabrail, Pierre Attali, Barbara Dauvois, Stefano Tamberi, Driffa Moussata, Angela Buonadonna, Emiliano Tamburini, Muhammet Ali, Armand Abergel, Albert Tran, Suayib Yalcin, Ursula Ehmer, Hermini Manzano, Jean Delwaide, Andrés Muñoz, Carlos López, Jean-Pierre Bronowicki, Zsolt Horváth, Alper Sevinc, Gloria Sánchez, Ralph Hauke, Gabriele Luppi, Bérangère Vasseur, Nelson S. Yee, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges], CHU Limoges, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital Charles Nicolle [Rouen]-CHU Rouen, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, P., Blanc, J. -F., Phelip, J. -M., Pelletier, G., Bronowicki, J. -P., Touchefeu, Y., Pageaux, G., Gerolami, R., Habersetzer, F., Nguyen-Khac, E., Casadei-Gardini, A., Borbath, I., Tran, A., Wege, H., Saad, A. S., Colombo, M., Abergel, A., Richou, C., Waked, I., Yee, N. S., Mole, A., Attali, P., Le Boulicaut, J., Vasseur, B., Moussata, D., Grange, J. -D., Ratziu, V., Khemissa-Akouz, F., Regnault, H., Dauvois, B., Zarski, J. -P., Ollivier-Hourmand, I., Manfredi, S., Debette-Gratien, M., Gangloff, A., Fontanges, T., Baron, A., Bouattour, M., Vincent, J., Sieghart, W., Maieron, A., Peeters, M., Delwaide, J., Lasser, L., Berg, T., Schultheiss, M., Zipprich, A., Trojan, J., Ehmer, U., Luppi, G., Luca, G., Tamberi, S., Amoroso, D., Alabiso, O., Buonadonna, A., Toniutto, P., Tamburini, E., Cubillo, A., Munoz, A., Guillen, C., Sanchez, G., Manzano, H., Navarro, V., Ales, I., Massuti, B., Dank, M., Bodoky, G., Kahan, Z., Horvath, Z., Gabrail, N., Ozer, H., Galanopoulos, C., Hauke, R., Raj, M., Harputluoglu, H., Sevinc, A., Goker, E., Coker, A., Yalcin, S., Ali, M., Ata, O., Tugba, I., Elkassas, M., Abdel, A., Wakid, I., Shamaa, S., El, N., Kohail, H., Makarem, J., Chehade, I., Farhat, F., Lopez, C., and Marin, M.
Subjects: Male, Gastroenterology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Clinical endpoint, Treatment Failure, ComputingMilieux_MISCELLANEOUS, education.field_of_study, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Antibiotics, Antineoplastic, Liver Neoplasms, Middle Aged, Sorafenib, 3. Good health, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, 030211 gastroenterology & hepatology, Female, medicine.drug, medicine.medical_specialty, Carcinoma, Hepatocellular, Neutropenia, Population, Antineoplastic Agents, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Carcinoma, medicine, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, education, Adverse effect, Aged, Hepatology, Dose-Response Relationship, Drug, business.industry, medicine.disease, Thrombocytopenia, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Doxorubicin, Asthenia, Nanoparticles, business
Abstract: Summary Background Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib therapy had failed. Methods We did a multicentre, open-label, randomised, controlled phase 3 trial at 70 sites in 11 countries. Patients with hepatocellular carcinoma with one or more previous systemic therapies, including sorafenib, were randomly assigned to receive 30 mg/m2 doxorubicin-loaded nanoparticles (30 mg/m2 group), 20 mg/m2 doxorubicin-loaded nanoparticles (20 mg/m2 group), or standard care using a computer-generated randomisation list prepared by the funder and stratified by geographic region. Patients in the experimental groups received perfusion of the drug every 4 weeks and those in the control group received any systemic anticancer therapy (except sorafenib) as per investigator decision. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the population of patients who received at least one dose of their assigned treatment. This trial is registered with ClinicalTrials.gov , number NCT01655693 . Findings Between June 15, 2012, and Jan 27, 2017, 541 patients were screened, of whom 144 were excluded and 397 were randomly assigned to one of the groups (133 to the 30 mg/m2 group; 130 to the 20 mg/m2 group; and 134 to the control group). Median follow-up was 22·7 months (IQR 11·2–34·9). After pooling the doxorubicin groups for the efficacy analysis, median overall survival was 9·1 months (95% CI 8·1–10·4) in the pooled doxorubicin-loaded nanoparticles group and 9·0 months (7·1–11·8) in the control group (HR 1·00 [95% CI 0·78–1·28], two-sided p=0·99). 227 (94%) of 242 patients who received doxorubicin-loaded nanoparticles and 100 (75%) of 134 patients in the control group had at least one treatment-emergent adverse event. The most common drug-related grade 3 or 4 treatment-emergent adverse events were neutropenia (25 [10%] of 242 treated with doxorubicin-loaded nanoparticles and eight [6%] of 134 in the control group), asthenia (six [2%] and four [3%]), and thrombocytopenia (three [1%] and ten [7%]). Six (2%) patients treated with doxorubicin-loaded nanoparticles and one (1%) of those in the control group were deemed by investigators to have had a drug-related death. Serious adverse events occurred in 74 (31%) patients who received doxorubicin-loaded nanoparticles and 48 (36%) in the control group. Interpretation Doxorubicin-loaded nanoparticles did not improve overall survival for patients with hepatocellular carcinoma in whom previous sorafenib treatment had failed. Funding Onxeo.
Published: 2019
Full Text: View/download PDF

32. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Author: Josep M. Llovet, Gerold Meinhardt, Valeriy Breder, Marie Aude Leberre, Tianqiang Song, Jean-Pierre Bronowicki, Gianluca Masi, Ann-Lii Cheng, György Bodoky, Jordi Bruix, Shukui Qin, René Gerolami, Isabelle Ollivier-Hourmand, Olivier Rosmorduc, Annette Baumhauer, Masatoshi Kudo, Osamu Yokosuka, Paul Ross, Marc Pracht, Philippe Merle, Richard S. Finn, Guohong Han, Alessandro Granito, Yi Hsiang Huang, and DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Subjects: Male, Niacinamide, Sorafenib, medicine.medical_specialty, Carcinoma, Hepatocellular, Pyridines, Population, Antineoplastic Agents, Kaplan-Meier Estimate, Placebo, Aged, Double-Blind Method, Female, Humans, Liver Neoplasms, Middle Aged, Phenylurea Compounds, Treatment Outcome, Medicine (all), law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Regorafenib, medicine, Clinical endpoint, education, education.field_of_study, Intention-to-treat analysis, business.industry, Carcinoma, Hepatocellular, General Medicine, Surgery, chemistry, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Liver function, business, medicine.drug
Abstract: none 24 si Published Online December 5, 2016 Background: There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We aimed to assess the efficacy and safety of regorafenib in patients with HCC who have progressed during sorafenib treatment. Methods: In this randomised, double-blind, parallel-group, phase 3 trial done at 152 sites in 21 countries, adults with HCC who tolerated sorafenib (≥400 mg/day for ≥20 of last 28 days of treatment), progressed on sorafenib, and had Child-Pugh A liver function were enrolled. Participants were randomly assigned (2:1) by a computer-generated randomisation list and interactive voice response system and stratified by geographical region, Eastern Cooperative Oncology Group performance status, macrovascular invasion, extrahepatic disease, and α-fetoprotein level to best supportive care plus oral regorafenib 160 mg or placebo once daily during weeks 1-3 of each 4-week cycle. Investigators, patients, and the funder were masked to treatment assignment. The primary endpoint was overall survival (defined as time from randomisation to death due to any cause) and analysed by intention to treat. This trial is registered with . ClinicalTrials.gov, number . NCT01774344. Findings: Between May 14, 2013, and Dec 31, 2015, 843 patients were screened, of whom 573 were enrolled and randomised (379 to regorafenib and 194 to placebo; population for efficacy analyses), and 567 initiated treatment (374 received regorafenib and 193 received placebo; population for safety analyses). Regorafenib improved overall survival with a hazard ratio of 0·63 (95% CI 0·50-0·79; one-sided p
Published: 2017
Full Text: View/download PDF

33. Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

Author: David Sefrioui, Julien Edeline, M. Baconnier, Karine Le Malicot, Barbara Dauvois, Alexandra Heurgue, Jean-Louis Jouve, Sébastien Dharancy, Julien Vergniol, Yves Rinaldi, Hervé Perrier, Maryline Debette-Gratien, Yves Becouarn, Mohamed Hebbar, Anthony Turpin, Christine Silvain, Côme Lepage, Thierry Lecomte, Gael Deplanque, Thierry de Baere, and Isabelle Ollivier-Hourmand
Subjects: medicine.medical_specialty, Carcinoma, Hepatocellular, Neutropenia, urologic and male genital diseases, Placebo, Placebo group, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Sunitinib, medicine, Humans, Chemoembolization, Therapeutic, Hepatology, business.industry, Liver Neoplasms, Liver failure, medicine.disease, Acute toxicity, Treatment Outcome, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Dose reduction, business, Liver Failure, medicine.drug
Abstract: Summary Background Trans-arterial chemoembolization (TACE) is one first-line option therapy for patients with hepatocellular carcinoma (HCC) not suitable for surgical resection. Aims We evaluated the effects of sunitinib plus doxorubicin-TACE on bleeding or liver failure. Methods Seventy-eight patients with HCC were included in this randomized, double-blind study. They received one to three TACE plus either sunitinib or placebo four weeks out of six for one year. The occurrence of severe bleeding or liver failure was assessed during the week after the TACE. The safety and survival outcomes were evaluated. Results No bleeding complication was reported. One and two liver failures were respectively observed in sunitinib and placebo patients. Compliance to sunitinib treatment was acceptable. Sunitinib dose reduction occurred in 37% of patients due to acute toxicity. Main grade 3–4 toxicities were: thrombocytopenia, neutropenia, increased bilirubin, increased ALT and asthenia. In the sunitinib group, the median PFS and OS were 9.05 [5.81;11.63] and 25.0 [13.5;36.8] months, respectively. In the placebo group, the median PFS and OS were 5.51 [4.14;7.79] and 20.5 [15.1;30.6] months, respectively. Conclusions TACE plus sunitinib in the first-line therapy for patients with HCC not suitable for surgical resection was feasible. ClinicalTrials.gov number NCT01164202.
Published: 2021
Full Text: View/download PDF

34. Hépatopathie chronique dans le spectre clinique de l’haplo-insuffisance en A20 (HA20) : description clinique et histopathologique à partir d’une famille française porteuse d’une nouvelle mutation de TNFAIP3

Author: Ines Elhani, N. Martin Silva, M. Trenec, A. Dumont, G. Grateau, Albertine Aouba, Serge Amselem, Samuel Deshayes, S. Georgin-Lavialle, Isabelle Ollivier, C. Bazille, Irina Giurgea, and H. De Boysson
Subjects: Gastroenterology, Internal Medicine
Abstract: Introduction Le TNF-α, apres sa fixation sur son recepteur membranaire, active la voie de signalisation NF-κB, cette voie activant a son tour la synthese de cytokines pro-inflammatoires. La proteine A20 est une enzyme de de-ubiquitination intervenant dans le retrocontrole negatif de cette voie. Des mutations heterozygotes du gene TNFAIP3, induisant l’haplo-insuffisance et le deficit fonctionnel de la proteine A20 (HA20), conduisent a une activation incontrolee de la voie NF-κB et a la production excessive de TNF- α, d’interleukine(IL)-1 et IL-6, et a des manifestations cliniques proches de celles des maladies de Behcet ou de Crohn. Neanmoins, le spectre clinique de cette tres rare maladie de description recente est en constante expansion par la description de nouveaux cas et profils immuno-cliniques et genetiques, objectif du present travail. Patients et methodes Nous decrivons retrospectivement l’eventail clinique et les caracteristiques histologiques hepatiques d’une famille de 8 patients atteints d’HA20 diagnostiquee sur une mutation pathogene privee inedite sur l’exon 2 du gene TNFAIP3 (c.259C > T ou p.(Arg87*)), dont 3 avaient une hepatopathie chronique fibrosante pour laquelle la recherche de l’ensemble des causes auto-immunes, metaboliques, infectieuses et environnementales etait revenue negative. Resultats La presentation clinique de ces 8 patients (8 femmes, âge median au diagnostic de 23 ans, symptomes inauguraux dans l’enfance a type d’aphtose) comprenait : une aphtose bipolaire (6/8) ou buccale (8/8), des anomalies auto-immunes (6/8, dont 5 avec une maladie auto-immune definie comme un diabete de type 1, une thyroidite d’Hashimoto ou une maladie de Biermer, et/ou 5 avec des anticorps antinucleaires ≥320), une pustulose/folliculite (5/8), des douleurs abdominales (4/8), des arthralgies (3/8), des adenopathies cervicales (3/8) et une pericardite recidivante (1/8). Trois patients avaient une hepatopathie chronique revelee par une cytolyse et une cholestase persistantes ou fluctuantes. L’echographie abdominale retrouvait une splenomegalie (n = 2), une hepatomegalie (n = 1) et/ou une atrophie hepatique (n = 1). La biopsie hepatique (n = 2) revelait un infiltrat inflammatoire lymphocytaire T dans les espaces portes, dans les sinusoides hepatiques et dans les canaux biliaires interlobulaires, et une atrophie periportale. Une biopsie cutanee sur des lesions folliculaires aigues retrouvait essentiellement un aspect de dermatite neutrophilique. Conclusion L’atteinte hepatique est exceptionnellement rapportee dans l’HA20 et seulement sporadique, avec a notre connaissance la description de 5 patients de 5 familles non apparentees. Cette atteinte semble etre secondaire a une atteinte de l’immunite adaptative, et ce travail demontre l’implication duale des immunites innee et adaptative dans les processus inflammatoires, respectivement cutanees neutrophiliques et hepatiques lymphocytaires dans cette maladie, et soutient, au-dela de l’activation specifique initiale de la voie du TNF- α, le caractere multi-cytokinique de la maladie. Enfin, nos donnees elargissent le spectre clinique de l’HA20 a la possibilite d’une hepatopathie chronique fibrosante specifique, et montrent que cette maladie rare recemment decrite cache probablement d’autres aspects cliniques et physiopathologiques a decouvrir et des patients avec presentation hepatique a depister.
Published: 2020
Full Text: View/download PDF

35. Combination of meld and lactates predicts early death in patients treated by salvage tips for refractory variceal bleeding

Author: Aurélie Walter, Marika Rudler, Pol Olivas, Lucile Moga, Eric Trépo, Marie-Angèle Robic, Isabelle Ollivier-Hourmand, Anna Baiges, Olivier Sutter, Charlotte Bouzbib, Jean Marie Peron, Vincent Le Pennec, Nathalie Ganne, Juan Carlos Garcia Pagan, Maxime Mallet, Metivier Sophie, Thong Dao, Dominique Thabut, Virginia Hernandez-Gea, Jean Charles Nault, Christophe Bureau, and Manon Allaire
Subjects: Hepatology
Published: 2020
Full Text: View/download PDF

36. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma

Author: Jean-Pierre Bronowicki, Jean-Louis Legoux, Thierry Lecomte, Jean-François Seitz, Olivier Bouché, Sylvain Manfredi, Prodige Investigators, Emilie Barbier, Jean-Marc Phelip, Eric Nguyen Khac, Ghassan Riachi, Isabelle Ollivier-Hourmand, Jacques Denis, Jean-Louis Jouve, Julien Vergniol, Anne-Laure Villing, Maryline Debette-Gratien, Jean-François Ramée, Roger Faroux, and Faiza Khemissa Akouz
Subjects: 0301 basic medicine, Oncology, Sorafenib, Adult, Diarrhea, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Antineoplastic Agents, Kaplan-Meier Estimate, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, neoplasms, Aged, Pravastatin, Aged, 80 and over, Univariate analysis, Hepatology, Performance status, business.industry, Liver Neoplasms, Middle Aged, medicine.disease, Prognosis, digestive system diseases, Progression-Free Survival, Clinical trial, 030104 developmental biology, Hepatocellular carcinoma, Quality of Life, 030211 gastroenterology & hepatology, Female, business, Liver cancer, medicine.drug, Follow-Up Studies
Abstract: Background & Aims Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). Combining sorafenib with another treatment, to improve overall survival (OS) within an acceptable safety profile, might be the next step forward in the management of patients with advanced HCC. We aimed to assess whether a combination of sorafenib and a statin improved survival in patients with HCC. Methods The objective of the PRODIGE-11 trial was to compare the respective clinical outcomes of the sorafenib-pravastatin combination (arm A) versus sorafenib alone (arm B) in patients with advanced HCC. Child-Pugh A patients with advanced HCC who were naive to systemic treatment (n = 323) were randomly assigned to sorafenib-pravastatin combination (n = 162) or sorafenib alone (n = 161). The primary endpoint was OS; secondary endpoints were progression-free survival, time to tumor progression, time to treatment failure, safety, and quality of life. Results After randomization, 312 patients received at least 1 dose of study treatment. After a median follow-up of 35 months, 269 patients died (arm A: 135; arm B: 134) with no difference in median OS between treatments arms (10.7 months vs. 10.5 months; hazard ratio = 1.00; p = 0.975); no difference was observed in secondary survival endpoints either. In the univariate analysis, the significant prognostic factors for OS were CLIP score, performance status, and quality of life scores. The multivariate analysis showed that the only prognostic factor for OS was the CLIP score. The main toxicity was diarrhea (which was severe in 11% of patients in arm A, and 8.9% in arm B), while severe nausea-vomiting was rare, and no toxicity-related deaths were reported. Conclusion Adding pravastatin to sorafenib did not improve survival in patients with advanced HCC. Lay summary Sorafenib has proven efficacy for the treatment of patients with advanced hepatocellular carcinoma. However, overall survival remains poor in these patients, so we were interested to see if the addition of a statin, pravastatin, improved outcomes in patients with advanced HCC. This randomized-controlled trial demonstrated that the sorafenib-pravastatin combination did not improve overall survival in this study population compared to sorafenib alone. Clinical trial number: NCT01075555.
Published: 2018

37. Infectious endocarditis in the case of cirrhosis: where do we stand?

Author: Ratmony Heng, Thong Dao, Armand Garioud, Manon Allaire, Isabelle Ollivier-Hourmand, and Jean-François Cadranel
Subjects: Liver Cirrhosis, medicine.medical_specialty, Cirrhosis, Heart disease, Population, Opportunistic Infections, 03 medical and health sciences, 0302 clinical medicine, Spontaneous bacterial peritonitis, Internal medicine, medicine, Endocarditis, Humans, Decompensation, 030212 general & internal medicine, education, education.field_of_study, Hepatology, business.industry, Gastroenterology, Endocarditis, Bacterial, medicine.disease, Prognosis, Cardiac surgery, Pneumonia, 030211 gastroenterology & hepatology, business
Abstract: Bacterial infections are common in the case of cirrhosis and represent a major cause of morbidity and mortality. The most frequent infections are spontaneous bacterial peritonitis, urinary tract infection, and pneumonia, but few data on infectious endocarditis are available. Infectious endocarditis is a rare event, and diagnosis can be made at all stages of Child-Pugh classification. In the case of cirrhosis, the clinical features and bacterial ecology are similar to that of the general population (two males/one female, preferential location on the aortic and mitral valves, history of heart disease, majority of Gram-positive bacteria), but in-hospital mortality is higher. The Child-Pugh score and a history of decompensation have been identified as independent predictive factors for in-hospital mortality and a Child-Pugh score more than C10 was associated with a higher risk of death. Less frequent use of aminoglycosides, rifampin, and cardiac surgery has been described in cirrhotic patients, probably because of potential toxicity. Nevertheless, as they are a cornerstone of therapy, prospective studies on the impact of these therapeutics are warranted to improve outcome in this population of patients.
Published: 2018

38. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective

Author: Victor de Ledinghen, Sophie Hillaire, Emilie Bérard, Anne Minello, Maeva Guillaume, Nassim Kamar, Véronique Loustaud-Ratti, David Saadoun, Brigitte Bernard-Chabert, Valérie Canva, Isabelle Ollivier-Hourmand, Laurent Alric, Vincent Leroy, Anaïs Vallet-Pichard, Marc Bourlière, Isabelle Fouchard-Hubert, Eric Nguyen-Khac, Stanislas Pol, Dominique Trias, Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Chirurgie Générale et Digestive [Purpan], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Foch [Suresnes], Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Chirurgie digestive, endocrinienne et générale [CHU Limoges], CHU Limoges, Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Département d'hépato-gastroentérologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service d'hépato-gastro-entérologie, Hôpital Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'Hépato-Gastroentérologie, CHU Amiens-Picardie, Service d'hépato-gastroentérologie [CHU Grenoble Alpes], Centre Hospitalier Universitaire [Grenoble] (CHU), Immunologie - Immunopathologie - Immunothérapie [CHU Pitié Salpêtrière] (I3), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Centre de Physiopathologie Toulouse Purpan (CPTP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD), CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Toulouse [Toulouse]-Hôpital de Rangueil, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Cochin [AP-HP]-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire, Immunologie - Immunopathologie - Immunothérapie (I3), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, Sustained Virologic Response, medicine.medical_treatment, 030232 urology & nephrology, Comorbidity, Hepacivirus, Severity of Illness Index, Liver disease, 0302 clinical medicine, Medicine, Aged, 80 and over, education.field_of_study, hemodialysis, Imidazoles, Middle Aged, 3. Good health, Drug Combinations, Grazoprevir, Nephrology, HCV, Female, 030211 gastroenterology & hepatology, Hemodialysis, Adult, medicine.medical_specialty, Elbasvir, Genotype, Population, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, elbasvir, 03 medical and health sciences, Quinoxalines, Internal medicine, Humans, Adverse effect, education, Aged, Benzofurans, Retrospective Studies, DAA, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, grazoprevir, Hepatitis C, Chronic, medicine.disease, Concomitant, Kidney Failure, Chronic, business, chronic kidney disease, Kidney disease
Abstract: IF 8.429 (2017); International audience; Patients with advanced chronic kidney disease who receive direct-acting antiviral drugs require special consideration regarding comorbid conditions. Here we assessed the efficacy and safety of grazoprevir plus elbasvir in 93 patients infected with HCV genotype 1 or 4 and with advanced chronic kidney disease in a non-randomized, multicenter, nationwide observational survey. Twenty patients with HCV genotype 1a, 51 patients with 1b, four unclassified genotype 1, 17 with genotype 4 and one with genotype 6 received grazoprevir plus elbasvir (100/50 mg) once daily. All patients had severe chronic kidney disease with 70 patients stage G5, including patients on hemodialysis (74.2%), and 23 were stage G4 chronic kidney disease. Severe liver disease (Metavir F3/F4) was found in 33 patients. A sustained virologic response 12 weeks after the end of therapy was achieved in 87 of 90 patients. Two patients had a virologic breakthrough and one had a relapse after treatment withdrawal. Most patients received many concomitant medications (mean 7.7) related to comorbid conditions. Serious adverse events occurred in six patients, including three deaths while on grazoprevir plus elbasvir, not related to this therapy. Thus, once-daily grazoprevir plus elbasvir was highly effective with a low rate of adverse events in this advanced chronic kidney disease difficult-to-treat population with an HCV genotype 1 or 4 infection.
Published: 2018
Full Text: View/download PDF

39. Suspicious liver nodule in chronic liver disease: Usefulness of a second biopsy

Author: Sophie Michalak, Boris Guiu, Isabelle Ollivier-Hourmand, B. Patouillard, Guillaume Baudin, Maxime Esvan, Valérie Vilgrain, L. Estivalet, P. Chevallier, A. Crouan, V. Le Pennec, Yves Gandon, C. Sylvain, A. Guillygomarc’h, Benoit Gallix, Eric Frampas, Christophe Duvoux, Franck Pilleul, Anne Minello, Isabelle Archambeaud, V. Cartier, R. Anty, Christophe Aubé, Jean-Pierre Tasu, Anita Paisant, M. Cuilleron, V. Brun, Alain Luciani, Jérôme Lebigot, Frédéric Oberti, Olivier Seror, J. Dumortie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Gabriel Montpied [Clermont-Ferrand], CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC AP-HP (hegp Ex-Broussais)/inserm, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service de radiologie et imagerie médicale [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Hôpital Beaujon, Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Hôpital l'Archet, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Henri Mondor, Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Pontchaillou [Rennes], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service d'Imagerie Diagnostique et de Radiologie Thérapeutique [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), RMN et optique : De la mesure au biomarqueur, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon], CHU Clermont-Ferrand, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes], and Hôpital Beaujon [AP-HP]
Subjects: Adult, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Biopsy, Chronic liver disease, 030218 nuclear medicine & medical imaging, Lesion, 03 medical and health sciences, 0302 clinical medicine, Fibrosis, Humans, Medicine, Radiology, Nuclear Medicine and imaging, In patient, Prospective Studies, Prospective cohort study, Aged, Aged, 80 and over, Radiological and Ultrasound Technology, medicine.diagnostic_test, business.industry, Liver Diseases, Liver Neoplasms, Nodule (medicine), General Medicine, Middle Aged, medicine.disease, 3. Good health, Hepatocellular carcinoma, Chronic Disease, Female, 030211 gastroenterology & hepatology, Radiology, medicine.symptom, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Purpose: To assess the usefulness of a second biopsy when the first one was inconclusive in patients with a liver nodule found during the follow-up for chronic liver disease.Materials and methods: Among 381 patients (544 nodules) included in a prospective study designed to evaluate the accuracy of imaging for the diagnosis of small hepatocellular carcinoma (HCC) in chronic liver disease, 254 nodules were biopsied. The following histological results were considered as conclusive: HCC, dysplastic or regenerative nodule, and other identified tumors (benign or malignant). For nodules with inconclusive results (e.g. fibrosis or no definite focal lesion), a second biopsy was suggested, but was not mandatory.Results: A total of 242 patients (194 men, 48 women; mean age, 61.9 +/- 9.5 [SD]; range: 40.2-89.0years) with 254 nodules underwent a first biopsy. Mean nodule diameter was 19.2 +/- 5.4mm (range: 10-33mm). The first biopsy was conclusive in 189/254 nodules (74.4%): 157 HCCs (83.1%), 11 regenerative nodules (5.8%), 10 dysplastic nodules (5.3%), 3 cholangiocarcinomas (1.6%), and 8 other tumors (4.2%). Among the 65 nodules for which the first biopsy was inconclusive, a second biopsy was performed for 17 nodules in 16 patients within 6 months of the first one. It was conclusive in 13/17 nodules (76.5%): 10 HCCs (76.9%), 2 dysplastic nodules (15.4%), and 1 other tumor (7.7%). In 4/17 nodules (23.5%), no definitive diagnosis could be provided.Conclusion: The diagnostic yield of a second biopsy of a suspicious lesion suggestive of HCC in chronic liver disease is not decreased compared to the first one. Repeated biopsy after a first negative one could be an alternative option to the follow-up of patients with chronic liver disease. (C) 2018 Societe francaise de radiologie
Published: 2018
Full Text: View/download PDF

40. Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy

Author: Jacques Ducos, Jacques Izopet, Valérie Garrigue, Florence Nicot, Isabelle Ollivier, Nassim Kamar, Romain Carcenac, Florence Abravanel, Peggy Perrin, Elodie Alessandri-Gradt, Karine Sauné, Odile Goria, Sébastien Lhomme, Caroline Lefebvre, Nicolas Jeanne, Michael Bismuth, Martine Dubois, Joelle Petitjean-Lecherbonnier, and Heidi Barth
Subjects: Adult, Genetic Markers, Male, 0301 basic medicine, Adolescent, viruses, RNA-dependent RNA polymerase, medicine.disease_cause, Antiviral Agents, Deep sequencing, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, Hepatitis E virus, Ribavirin, medicine, Humans, Pharmacology (medical), Child, Letter to the Editor, Polymerase, Aged, Aged, 80 and over, Pharmacology, Base Sequence, biology, Sequence Analysis, RNA, business.industry, virus diseases, Middle Aged, RNA-Dependent RNA Polymerase, Hepatitis E, medicine.disease, Virology, digestive system diseases, Chronic infection, Treatment Outcome, 030104 developmental biology, Infectious Diseases, chemistry, Mutation, Mutation (genetic algorithm), biology.protein, RNA, Viral, Female, business
Abstract: Hepatitis E virus (HEV) can lead to chronic infection in solid-organ transplant patients. Ribavirin is efficient for treatment of chronically infected patients. Recently, the1634R mutation in the HEV polymerase has been associated with treatment failure. However, it is unclear if this mutation can be used as a prognostic marker of treatment outcome. We studied the prevalence of the 1634R mutation in the HEV polymerase of patients starting ribavirin therapy, the influence of the 1634R variants on the viral response, the frequency of the 1634R mutation in patients whose treatment failed, and its impact on ribavirin retreatment. We analyzed pretreatment samples from 63 solid-organ transplant patients with chronic hepatitis E using deep sequencing; 42 patients had a sustained virologic response (SVR), and 21 were non-SVR patients. We detected the 1634R variant by deep sequencing in 36.5% (23/63) of the patients (proportions, 1.3 to 100%). The 1634R variant was detected in 31.0% (13/42) of baseline plasma samples from patients with SVR and in 47.6% (10/21) in the other patients ( P = 0.2). The presence of this mutation did not influence the initial decrease in viral RNA. Lastly, a second prolonged ribavirin treatment led to SVR in 70% of the patients who initially did not have SVR, despite the presence of the 1634R variant. We conclude that the presence of the 1634R variant at ribavirin initiation does not lead to absolute ribavirin resistance. Although its proportion increased in patients whose treatment failed, the presence of the 1634R variant did not compromise the response to a second ribavirin treatment.
Published: 2016
Full Text: View/download PDF

41. Retrospective evaluation of prognostic score performances in cirrhotic patients admitted to an intermediate care unit

Author: Thong Dao, Isabelle Ollivier-Hourmand, Nicolas Terzi, Maxime Delvincourt, Mamadou Koné, Marie-Astrid Piquet, Damien du Cheyron, Benoît Dupont, Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), MTCT-Plus programme (ACONDA), MTCT-Plus programme, Service de réanimation médicale [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Service d’Hépato-Gastroentérologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Bioénergétique fondamentale et appliquée, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)
Subjects: medicine.medical_specialty, Cirrhosis, Hepatology, Receiver operating characteristic, business.industry, [SDV]Life Sciences [q-bio], Mortality rate, Gastroenterology, SAPS III, medicine.disease, Intensive care unit, Surgery, law.invention, Liver disease, law, SAPS II, Internal medicine, medicine, Simplified Acute Physiology Score, business, ComputingMilieux_MISCELLANEOUS
Abstract: Background The prognosis of cirrhotic patients in the Intensive Care Unit requires the development of predictive tools for mortality. We aimed to evaluate the ability of different prognostic scores to predict hospital mortality in these patients. Methods A single-centre retrospective analysis was conducted of 281 hospital stays of cirrhotic patients at an Intermediate Care Unit between June 2009 and December 2010. The performance of the Simplified Acute Physiology Score (SOFA), the Simplified Acute Physiology Score (SAPS) II or III, Child–Pugh, Model for End-Stage Liver Disease (MELD), MELD-Na and the Chronic Liver Failure-Consortium Acute-on-Chronic Liver Failure score (CLIF-C ACLF) in predicting hospital mortality were compared. Results Mean age was 58.2 ± 12.1 years; 77% were male. The main cause of admission was acute gastrointestinal bleeding (47%). The in-hospital mortality rate was 25.3%. Receiver operating characteristic curve analyses demonstrated that SOFA (0.82) MELD-Na (0.82) or MELD (0.81) scores at admission predicted in-hospital mortality better than Child–Pugh (0.76), SAPS II (0.77), SAPS III (0.75) or CLIF-C ACLF (0.75). We then developed the cirrhosis prognostic score (Ci-Pro), which performed better (0.89) than SOFA. Conclusion SOFA, MELD and especially the Ci-Pro score show the best performance in predicting hospital mortality of cirrhotic patients admitted to an Intermediate Care Unit.
Published: 2015
Full Text: View/download PDF

42. Severe liver failure rather than cirrhosis is associated with mortality in patients with infectious endocarditis: a retrospective case-control study

Author: Christophe Bureau, Je Combining Acute Accent Rôme Dumortier, Anis Sfaxi, Manon Allaire, Laurent Spahr, Jacques Denis, Vincent Di Martino, Gilles Macaigne, Jean-Pierre Bronowicki, Jean-Didier Grangé, Vincent Jouannaud, Salah Zerkly, Teresa Antonini, Isabelle Ollivier-Hourmand, Alexandre Pariente, Alexandre Louvet, He Combining Acute Accent le Combining Grave Accent Ne Blasco-Perrin, Pierre Iaria, Karine Dupont, Jean-Baptiste Nousbaum, Carine Chagneau-Derrode, Agne Combining Grave Accent S Pe Combining Acute Accent Laquier, Patrice Cacoub, Thierry Thevenot, Je Combining Acute Accent Rome Gournay, Jean-François Cadranel, Thong Dao, Ryme Chentouh, Christine Silvain, Isabelle Rosa-He Combining Acute Accent Zode, Nathalie Ganne-Carrie Combining Acute Accent, Xavier Causse, Marc Bourlie Combining Grave Accent Re, Laurent Alric, Armand Garioud, Hortensia Lison, Pagès, Nathalie, Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Lab Excellence Inflamex (CRI INSERM U1149 - Bichat Medical Faculty), Université Paris Diderot - Paris 7 (UPD7), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre hospitalier de Pau, Centre Hospitalier de Montélimar, CH Montélimar, Centre Hospitalier Universitaire Marseille, CHU Marseille, Centre Hospitalier Régional d'Orléans (CHRO), CHU Brest - Service hépato-gastro-entérologie (CHU de Brest) (CHU Brest - Service hépato-gastro-entérologie), CHU Lyon Croix-Rousse, Hospices civils de Lyon, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Intercommunal de Créteil (CHIC), Centre hospitalier universitaire de Bondy, CHU Bondy, Service de Cardiologie, Centre Hospitalier Lagny-Marne la Vallée, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hépato-Biliaire [Hôpital Paul Brousse] (CHB), Hôpital Paul Brousse-Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de chirurgie digestive et viscérale [Corbeil-Essonnes], Centre Hospitalier Sud Francilien, CH Evry-Corbeil-CH Evry-Corbeil, and Group Hospitalier public Sud Oise GHPSO (Creil)
Subjects: Liver Cirrhosis, Male, Cirrhosis, [SDV]Life Sciences [q-bio], Severity of Illness Index, Bacterial / drug therapy, 0302 clinical medicine, Risk Factors, Liver Cirrhosis / complications, Hospital Mortality, Liver Failure / mortality, Heart Diseases / epidemiology, Endocarditis, Gastroenterology, Bacterial / mortality, Middle Aged, 3. Good health, [SDV] Life Sciences [q-bio], Liver Failure / physiopathology, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, France, Switzerland, medicine.medical_specialty, Heart Diseases, MEDLINE, Switzerland / epidemiology, 03 medical and health sciences, France / epidemiology, Internal medicine, Severity of illness, medicine, Humans, In patient, Cardiac Surgical Procedures, Aged, Retrospective Studies, Hepatology, business.industry, Case-control study, Liver failure, Retrospective cohort study, Endocarditis, Bacterial, medicine.disease, Bacterial / complications, Liver Cirrhosis / mortality, Case-Control Studies, business, Liver Failure
Abstract: International audience; Background: Data on infectious endocarditis (IE) in patients with liver cirrhosis (LC) are sparse. We aimed to describe the characteristics and predictors of mortality from IE in patients with LC.Patients and methods: Overall, 101 patients with LC and 101 controls with IE matched for sex, age, date of IE, and diabetes were retrospectively selected in 23 liver units between 2000 and 2013.Results: Mean age was 60.8±10.5 and 60.6±11.5 years in LC and controls, respectively. Causes of cirrhosis (Child-Pugh A/B/C: 10.4%/41.7%/47.9%, MELD score: 17±7.8) were excess alcohol intake (79.6%), viral hepatitis (17.3%), and metabolic syndrome (14.3%). Previous history of cardiopathy was found in 24.8% of LC (prosthetic valve 8.9%) and 37.6% of controls (P=0.07). The most frequent bacteria involved were gram-positive cocci. LC had significantly fewer aminoglycosides (P=0.0007), rifamycin (P=0.03), and valve surgery (P=0.02) than controls. The proportion of patients who died following cardiac surgery was similar between the two groups (9.7% for LC vs. 8.7% for controls, P=1). In-hospital mortality for Child-Pugh C patients was significantly higher than controls (61.4 vs. 23%, P
Published: 2018

43. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

Author: Jean-Pierre Zarski, Raoul Poupon, Christine Silvain, Victor de Ledinghen, Dominique Rainteau, Sylvie Chollet-Martin, Fabien Zoulim, Odile Goria, Armand Abergel, Gisèle N'Kontchou, Pascal Potier, François Habersetzer, Guillaume Lefèvre, Anne Minello, Farid Gaouar, Olivier Roux, Eric Nguyen-Khac, Olivier Chazouillères, Jérôme Boursier, Lydie Humbert, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Sara Lemoinne, Maryline Debette-Gratien, Dominique Larrey, Christophe Corpechot, Luc de Chaisemartin, Philippe Mathurin, Alexandra Rousseau, Alexandra Heurgué-Berlot, Farid-Hakeem Admane, Tabassome Simon, Antonia Le Gruyer, Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Référence des Maladies Rares - Maladies Inflammatoires des Voies Biliaires et Service d’Hépatologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche Clinique de l’Est Parisien [CHU Saint-Antoine] (URC-EST), Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire [Rennes], Hôpital Claude Huriez [Lille], CHU Lille, CHU Rouen, Normandie Université (NU), Service d'hépato-gastro-entérologie et oncologie digestive [CHR Orléans], Centre Hospitalier Régional d'Orléans (CHRO), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre hospitalier universitaire de Poitiers (CHU Poitiers), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges], CHU Limoges, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nancy (CHU Nancy), Service d’Hépato-Gastroentérologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Service d'hépato-gastro-entérologie [CHU Haut-Lévêque], Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux]-CHU Bordeaux [Bordeaux], Hôpital Robert Debré, Service d'Hépato-gastroentérologie, 51092 Reims, France, affiliation inconnue, Service d'Hépato-gastroentérologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'hépato-gastroentérologie [CHU Grenoble Alpes], Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris-Sud - Paris 11 (UP11), Laboratoire des biomolécules (LBM UMR 7203), Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Département de Chimie - ENS Paris, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Chimie Moléculaire de Paris Centre (FR 2769), Institut de Chimie du CNRS (INC)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Immunologie 'Autoimmunité et Hypersensibilités' [AP-HP Hôpital Bichat, Paris], AP-HP - Hôpital Bichat - Claude Bernard [Paris], and Sorbonne Université (SU)
Subjects: Liver Cirrhosis, Male, Cirrhosis, Cholangitis, Biliary/complications/drug therapy, Obeticholic Acid, Placebo-controlled study, Gastroenterology, Placebos, chemistry.chemical_compound, Liver disease, 0302 clinical medicine, Treatment Failure, Bezafibrate/adverse effects/*therapeutic use, Multicenter, Hypolipidemic Agents/adverse effects/*therapeutic use, Hypolipidemic Agents, Combination Therapy, medicine.diagnostic_test, Liver Cirrhosis, Biliary, Ursodeoxycholic Acid, Obeticholic acid, General Medicine, Middle Aged, Prognosis, Ursodeoxycholic acid, 3. Good health, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, medicine.drug, Adult, medicine.medical_specialty, Outcomes, Placebo, Biochemical Response, Bile Acids and Salts, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Cholangitis/*drug therapy/etiology, Humans, Placebos/therapeutic use, Prothrombin time, Bezafibrate, business.industry, Ursodeoxycholic Acid/therapeutic use, medicine.disease, Renal-Function, Bile Acids and Salts/blood, chemistry, Fenofibrate Therapy, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: IF 79.258 (2017); International audience; Background : Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which are agonists of peroxisome proliferator–activated receptors, in combination with ursodeoxycholic acid, have shown potential benefit in patients with this condition.Methods : In this 24-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 100 patients who had had an inadequate response to ursodeoxycholic acid according to the Paris 2 criteria to receive bezafibrate at a daily dose of 400 mg (50 patients), or placebo (50 patients), in addition to continued treatment with ursodeoxycholic acid. The primary outcome was a complete biochemical response, which was defined as normal levels of total bilirubin, alkaline phosphatase, aminotransferases, and albumin, as well as a normal prothrombin index (a derived measure of prothrombin time), at 24 months.Results : The primary outcome occurred in 31% of the patients assigned to bezafibrate and in 0% assigned to placebo (difference, 31 percentage points; 95% confidence interval, 10 to 50; P
Published: 2018
Full Text: View/download PDF

44. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis

Author: Richard, Moreau, Laure, Elkrief, Christophe, Bureau, Jean-Marc, Perarnau, Thierry, Thévenot, Faouzi, Saliba, Alexandre, Louvet, Pierre, Nahon, Adrien, Lannes, Rodolphe, Anty, Sophie, Hillaire, Blandine, Pasquet, Violaine, Ozenne, Marika, Rudler, Isabelle, Ollivier-Hourmand, Marie Angèle, Robic, Louis, d'Alteroche, Vincent, Di Martino, Marie-Pierre, Ripault, Arnaud, Pauwels, Jean-Didier, Grangé, Nicolas, Carbonell, Jean-Pierre, Bronowicki, Audrey, Payancé, Pierre-Emmanuel, Rautou, Dominique, Valla, Nathalie, Gault, and Didier, Lebrec
Subjects: Liver Cirrhosis, Male, Time Factors, Incidence, Ascites, Kaplan-Meier Estimate, Middle Aged, Anti-Bacterial Agents, Treatment Outcome, Double-Blind Method, Humans, Female, France, Prospective Studies, Gram-Negative Bacterial Infections, Norfloxacin, Proportional Hazards Models
Abstract: There is debate over the effects of long-term oral fluoroquinolone therapy in patients with advanced cirrhosis. We performed a randomized controlled trial to evaluate the effects of long-term treatment with the fluoroquinolone norfloxacin on survival of patients with cirrhosis.We performed a double-blind trial of 291 patients with Child-Pugh class C cirrhosis who had not received recent fluoroquinolone therapy. The study was performed at 18 clinical sites in France from April 2010 through November 2014. Patients were randomly assigned to groups given 400 mg norfloxacin (n = 144) or placebo (n = 147) once daily for 6 months. Patients were evaluated monthly for the first 6 months and at 9 months and 12 months thereafter. The primary outcome was 6-month mortality, estimated by the Kaplan-Meier method, censoring spontaneous bacterial peritonitis, liver transplantation, or loss during follow-up.The Kaplan-Meier estimate for 6-month mortality was 14.8% for patients receiving norfloxacin and 19.7% for patients receiving placebo (P = .21). In competing risk analysis that took liver transplantation into account, the cumulative incidence of death at 6 months was significantly lower in the norfloxacin group than in the placebo group (subdistribution hazard ratio, 0.59; 95% confidence interval, 0.35-0.99). The subdistribution hazard ratio for death at 6 months with norfloxacin vs placebo was 0.35 (95% confidence interval, 0.13-0.93) in patients with ascites fluid protein concentrations15 g/L and 1.39 (95% confidence interval, 0.42-4.57) in patients with ascites fluid protein concentrations ≥15 g/L. Norfloxacin significantly decreased the incidence of any and Gram-negative bacterial infections without increasing infections caused by Clostridium difficile or multiresistant bacteria.In a randomized controlled trial of patients with advanced cirrhosis without recent fluoroquinolone therapy, norfloxacin did not reduce 6-month mortality, estimated by the Kaplan-Meier method. Norfloxacin, however, appears to increase survival of patients with low ascites fluid protein concentrations. ClinicalTrials.gov ID: NCT01037959.
Published: 2017

45. Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo

Author: Tianqiang Song, M Pracht, Jean-Pierre Bronowicki, Gianluca Masi, MA LeBerre, Guohong Han, René Gerolami, Osamu Yokosuka, Peter R. Galle, Masatoshi Kudo, Philippe Merle, Gerold Meinhardt, Paul Ross, György Bodoky, Alessandro Granito, Y.-H. Huang, Isabelle Ollivier-Hourmand, Jordi Bruix, and S Qin
Subjects: Sorafenib, Oncology, medicine.medical_specialty, Second line treatment, business.industry, Placebo, medicine.disease, chemistry.chemical_compound, chemistry, Tumor progression, Regorafenib, Internal medicine, Hepatocellular carcinoma, Medicine, In patient, business, medicine.drug
Published: 2017
Full Text: View/download PDF

46. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: A randomized controlled trial

Author: C. Chagneau-Derrode, Emmanuel Rusch, Anne Minello, Rodolphe Anty, Pierre Bernard, Louis d’Alteroche, Armand Abergel, Jérôme Gournay, Amélie Le Gouge, Jean Ayoub, Faouzi Saliba, Bruno Giraudeau, Patrick Borentain, Charlotte Nicolas, Isabelle Ollivier-Hourmand, Christophe Gaborit, and Perarnau Jm
Subjects: medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, medicine.medical_treatment, Stent, medicine.disease, Surgery, Stenosis, Ascites, medicine, Clinical endpoint, Portal hypertension, medicine.symptom, business, Transjugular intrahepatic portosystemic shunt, Hepatic encephalopathy
Abstract: Background & Aims The first studies comparing covered stents (CS) and bare stents (BS) to achieve Transjugular Intrahepatic Portosystemic Shunt (TIPS) were in favor of CS, but only one randomized study has been performed. Our aim was to compare the primary patency of TIPS performed with CS and BS. Methods The study was planned as a multicenter, pragmatic (with centers different in size and experience), randomized, single-blinded (with blinding of patients only), parallel group trial. The primary endpoint was TIPS dysfunction defined as either a portocaval gradient ⩾12mmHg, or a stent lumen stenosis ⩾50%. A transjugular angiography with portosystemic pressure gradient measurement was scheduled every 6months after TIPS insertion. Results 137 patients were randomized: 66 to receive CS, and 71 BS. Patients who were found to have a hepato-cellular carcinoma, or whose procedure was cancelled were excluded, giving a sample of 129 patients (62 vs. 67). Median follow-up for CS and BS were 23.6 and 21.8months, respectively. Compared to BS, the risk of TIPS dysfunction with CS was 0.60 95% CI [0.38–0.96], ( p =0.032). The 2-year rate of shunt dysfunction was 44.0% for CS vs. 63.6% for BS. Early post TIPS complications (22.4% vs. 34.9%), risk of hepatic encephalopathy (0.89 [0.53–1.49]) and 2-year survival (70% vs. 67.5%) did not differ in the two groups. The 2-year cost/patient was 20k€ [15.9–27.5] for CS vs. 23.4k€ [18–37] for BS ( p =0.52). Conclusions CS provided a significant 39% reduction in dysfunction compared to BS. We did not observe any significant difference with regard to hepatic encephalopathy or death.
Published: 2014
Full Text: View/download PDF

47. 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment

Author: György Bodoky, Guohong Han, Tianqiang Song, Philippe Merle, Isabelle Ollivier-Hourmand, Jean-Pierre Bronowicki, Shukui Qin, Gianluca Masi, René Gerolami, Valeriy Breder, Olivier Rosmorduc, Annette Baumhauer, Jordi Bruix, Paul Ross, Osamu Yokosuka, Gerold Meinhardt, Yi Hsiang Huang, Masatoshi Kudo, Alessandro Granito, and MA LeBerre
Subjects: Oncology, medicine.medical_specialty, business.industry, Sorafenib treatment, medicine.disease, Placebo, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Regorafenib, Hepatocellular carcinoma, Internal medicine, medicine, Overall survival, Radiology, Nuclear Medicine and imaging, Cardiology and Cardiovascular Medicine, business, 030217 neurology & neurosurgery
Published: 2018
Full Text: View/download PDF

48. SAT-007-Survival and risk factors of mortality after emergency transjugular intrahepatic portosystemic shunt for uncontrolled acute variceal bleeding caused by cirrhosis-related portal hypertension

Author: Isabelle Ollivier-Hourmand, Olivier Sutter, Roland Amathieu, Olivier Seror, Jean-Charles Nault, Cléa Rouillon, Thong Dao, Nathalie Ganne, Manon Allaire, and Aurélie Walter
Subjects: medicine.medical_specialty, Variceal bleeding, Cirrhosis, Hepatology, business.industry, medicine.medical_treatment, Internal medicine, medicine, Portal hypertension, medicine.disease, business, Gastroenterology, Transjugular intrahepatic portosystemic shunt
Published: 2019
Full Text: View/download PDF

49. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

Author: Eric Nguyen-Khac, Olivier Chazouillères, Dominique Larrey, Isabelle Ollivier-Hourmand, Armando Abergel, Alexandra Rousseau, Tabassome Simon, Anne Minello, François Habersetzer, Christophe Corpechot, Dominique Guyader, Fabien Zoulim, Odile Goria, Olivier Roux, Gisèle N'Kontchou, Jean-Pierre Bronowicki, C. Silvain, Farid Gaouar, Jean-Pierre Zarski, R.E. Poupon, V. de Ledhingen, Patrick Potier, Alexandra Heurgué-Berlot, Maryline Debette-Gratien, P. Mathurin, Jérôme Boursier, Maladies fibro-inflammatoires d’origine métabolique et biliaire du foie [CRSA], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS - UM 4 (UMR 8258 / U1022)), Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], CHU Pontchaillou [Rennes], Interactions Virus-Hôte et Maladies Hépatiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre Hospitalier Régional d'Orléans (CHRO), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire Inflammation, Tissus épithéliaux et Cytokines (LITEC), Université de Poitiers, Institut d'astrophysique spatiale (IAS), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National d’Études Spatiales [Paris] (CNES), Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges], CHU Limoges, Cellules souches normales et cancéreuses, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Reims (CHU Reims), Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CIC AP-HP (hegp Ex-Broussais)/inserm, Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire [Grenoble] (CHU), Hôpital Jean Verdier [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: medicine.medical_specialty, Bezafibrate, animal structures, Hepatology, business.industry, health care facilities, manpower, and services, [SDV]Life Sciences [q-bio], education, Placebo-controlled study, Gastroenterology, Ursodeoxycholic acid, Double blind, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, In patient, business, health care economics and organizations, medicine.drug
Abstract: International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver-Disease, Amsterdam, NETHERLANDS, APR 19-23, 2017; International audience
Published: 2017
Full Text: View/download PDF

50. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities

Author: Valérie Bourcier, Sylvie Chevret, Jean-Pierre Bronowicki, Jean-Pierre Vinel, Isabelle Ollivier, Valérie Vilgrain, Cendrine Chaffaut, Sophie Hillaire, Philippe Mathurin, Paul Calès, Jean-Claude Trinchet, Ariane Mallat, Michel Beaugrand, Dominique Roulot, Françoise Degos, Gisèle N'Kontchou, Hélène Fontaine, Jean Henrion, Service d'hépato-gastroentérologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hopital Saint-Louis [AP-HP] (AP-HP), Hôpital Jean Verdier [AP-HP], Université Paris Nord (Paris 13), Service d'hépatologie, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital de Jolimont, Hopital de Jolimont, Service d'hépatologie médicale [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Service de Gastro-entérologie [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Foch [Suresnes], Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro-entérologie - Hépatologie [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Service d'Hépato-gastroentérologie, Hôpital Huriez-Université de Lille, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre de recherche biomédicale Bichat-Beaujon (CRB3), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'imagerie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP], Biostatistique et épidemiologie clinique, UFR Santé, Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord, Service d’Hépatologie [Hôpital Beaujon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Université Paris 13 (UP13), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Beaujon, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP]
Subjects: Liver Cirrhosis, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Cirrhosis, [SDV]Life Sciences [q-bio], medicine.disease_cause, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Belgium, Randomized controlled trial, law, Internal medicine, Carcinoma, Humans, Medicine, Cumulative incidence, Early Detection of Cancer, Ultrasonography, Hepatitis B virus, Hepatology, business.industry, Incidence, Incidence (epidemiology), Liver Neoplasms, Middle Aged, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Female, 030211 gastroenterology & hepatology, France, alpha-Fetoproteins, Radiology, business, Follow-Up Studies
Abstract: International audience; Detection of small hepatocellular carcinoma (HCC) eligible for curative treatment is increased by surveillance, but its optimal periodicity is still debated. Thus, this randomized trial compared two ultrasonographic (US) periodicities: 3 months versus 6 months. A multicenter randomized trial was conducted in France and Belgium (43 sites). Patients with histologically proven compensated cirrhosis were randomized into two groups: US every 6 months (Gr6M) or 3 months (Gr3M). For each focal lesion detected, diagnostic procedures were performed according to European Association for the Study of the Liver guidelines. Cumulative incidence of events was estimated, then compared using Gray's test. The prevalence of HCC ≤30 mm in diameter was the main endpoint. A sample size of 1,200 patients was required. A total of 1,278 patients were randomized (Gr3M, n = 640; Gr6M, n = 638; alcohol 39.2%, hepatitis C virus 44.1%, hepatitis B virus 12.5%). At least one focal lesion was detected in 358 patients (28%) but HCC was confirmed in only 123 (9.6%) (uninodular 58.5%, ≤30 mm in diameter 74%). Focal-lesion incidence was not different between Gr3M and Gr6M groups (2-year estimates, 20.4% versus 13.2%, P = 0.067) but incidence of lesions ≤10 mm was increased (41% in Gr3M versus 28% in Gr6M, P = 0.002). No difference in either HCC incidence (P = 0.13) or in prevalence of tumors ≤30 mm in diameter (79% versus 70%, P = 0.30) was observed between the randomized groups. Conclusion: US surveillance, performed every 3 months, detects more small focal lesions than US every 6 months, but does not improve detection of small HCC, probably because of limitations in recall procedures. (HEPATOLOGY 2011;)
Published: 2011
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

90 results on '"Isabelle Ollivier"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources